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Zusammenfassung 
Neuronale Netzwerke sind mit verschiedenen spannungsgesteuerten Kalziumkanälen 
verknüpft, die eine Schlüsselrolle in der Entstehung von Oszillationen im Hippocampus, 
aber auch in der thalamokortikalen Rhythmizität einnehmen. Innerhalb einer Vielzahl 
von Oszillationen konnte gezeigte werden, dass der Cav2.3 R-typ Kalziumkanal für die 
hippocampale Thetaaktivität maßgeblich verantwortlich ist. Thetaoszillationen im 
Frequenzbereich von 4-7 Hz repräsentieren ein spezifisches Aktivitätsmuster, das für 
kognitive Fertigkeiten, wie dem Abrufen von Gedächtnisinhalten, unerlässlich ist. Auf 
pharmakologischer Ebene werden zwei Subtypen von Thetaaktivität, der Atropin 
resistente Typ I und das Atropin sensitive Typ II Theta, differenziert. Typ II Theta wird 
dabei über eine durch den Cav2.3 R-typ Kalziumkanal vermittelte, muskarinerge 
Signalkaskade in der hippocampalen CA1 Region generiert. Interessanterweise treten 
Theta Oszillationen auch während des paradoxen bzw. REM (rapid eye movement) 
Schlafs auf, was daraufhin deutet, dass Thetaaktivität vom zirkadianen Rhythmus 
abhängt. Da Cav2.3 R-typ Kalziumkanäle ebenfalls im retikulär thalamischen Kern 
(RTN), der in die Schlafgenerierung eingebunden ist, exprimiert werden, kann vermutet 
werden, dass dem Cav2.3 Kalziumkanal eine regulatorische Funktion beim Schlaf 
zukommt. Bislang konnte allerdings nicht geklärt werden, welche genaue Rolle Cav2.3 
R-typ Kalziumkanäle im thalamokortikalen Netzwerk übernehmen. Daher analysierten 
wir den Cav2.3 R-typ Kalziumkanal in spontanen und pharmakologisch induzierten 
Schlaf von Cav 2.3
-/-
 Mäusen und Cav 2.3
+/+
 Kontrolltieren. Unsere Ergebnisse zeigen 
eine erhöhte Anzahl an Schlafübergängen sowie eine verminderte Gesamtwachdauer bei 
Cav 2.3
-/-
 Mäusen und verdeutlichen folglich die tragende Rolle des Cav2.3 R-typ 
Kalziumkanals in Bezug auf die Schlafmodulation.   
Studien belegen, dass Cav2.3
-/-
 Mäuse auch Absence-Epilepsien ausbilden können, was 
die Rolle des Cav2.3 R-typ Kalziumkanals in der Epileptogenese widerspiegelt. 
Pathologische Veränderungen in der zentralen Rhythmizität und eine damit 
einhergehende erhöhte Anfallswahrscheinlichkeit können unter anderem durch 
Akkumulation von Aß Plaques, wie sie bei der Alzheimererkrankung auftreten, 
gefördert werden. Dabei zeigte sich, dass in Mausmodellen der familiären Alzheimer-
Demenz (FAD) erhöhte Aß Plaquebildung mit Veränderungen in der Proteinsynthese 
vom BACE1 Enzym (ß-site APP cleaving enzyme 1) einhergeht. In diesem 
Zusammenhang ist eine gesteigerte Translation des BACE1 Enzyms unmittelbar an die 
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Phosphorylierung vom Serin an Position 51 des eukaryotischen 
Translationsinitiationsfaktors 2 Alpha (elF2α) gebunden. Diese Tatsache wirft die Frage 
auf, ob eine Runterregulierung von elF2α zu einer geringeren Anfallswahrscheinlichkeit 
durch verminderte Plaquebildung beiträgt und somit den kognitiven Verfall in 5XFAD 
Mäusen verzögern kann. Dazu untersuchten wir mögliche präventive Effekte von elF2α 
auf die Epileptogenese, indem wir 5XFAD Mäuse mit einer elF2αS51A Knock-in Line 
kreuzten, bei denen, durch eine Substitution von Serin durch Alanin an Position 51 
bedingt,  elF2α nicht mehr phosphoryliert werden kann. Unsere Ergebnisse zeigen einen 
limitierten präventiven Effekt von elF2α auf motorische und kognitive Defizite in 
5XFAD Mäusen. Veränderungen im Hippocampus gehen mit elektrophysiologischen 
Befunden einher, welche nicht-konvulsive Statusformen epileptiformer Aktivität bei 
5XFAD Tieren mit elF2αS51A Allel belegen. Weiterhin untersuchten wir, wie sich 
Anfallsaktivität auf die muskaringere Signalkaskade in 5XFAD Mäusen auswirkt. Wir 
stellten fest, dass eine verstärkte muskarinerge Signalkaskade sowohl zu neuronaler 
Dysrhythmie, aber auch zu einer Erhöhung von Atropin sensitiven Typ II Theta beiträgt, 
die als möglicher Kompensationsmechanismus zu einem dysbalancierten neuronalen 
System bei Morbus Alzheimer in Betracht gezogen werden kann.  
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Abstract 
Neuronal networks are strongly connected to voltage-gated Ca
2+
 channels which are key 
elements in mediating hippocampal oscillations and thalamocortical rhythmicity. 
Among different brain oscillations the Cav2.3 R-type Ca
2+
 channel turned out to be 
responsible for hippocampal theta activity. Theta oscillations occurring at a frequency 
range of 4-7 Hz represent a specific activity pattern playing a crucial role in cognition, 
such as memory retrieval. Pharmacologically, theta activity can be differentiated into 
two different subtypes, atropine resistant type I and atropine sensitive type II. In the 
hippocampal CA1 region type II theta is mediated by voltage-gated Cav2.3 R-type Ca
2+
 
channels via the muscarinic signaling cascade. Interestingly, theta oscillations can also 
be measured during rapid eye movement (REM) sleep indicating that theta rhythms are 
triggered in a circadian rhythm-dependent manner. Because Cav2.3 R-type Ca
2+
 
channels are also expressed in the reticular thalamic nucleus (RTN), which is 
responsible for sleep initiation, it can be hypothesized that the Cav2.3 R-type Ca
2+
 
channel might be essentially involved in sleep regulation. However, the detailed 
functional role of Cav2.3 R-type Ca
2+
 channels in the thalamocortical network still 
remains unclear. Therefore, we analyzed Cav2.3 R-type Ca
2+
 channels in Cav2.3
-/-
 mice 
and controls in spontaneous and artificial, urethane induced sleep, using implantable 
video-EEG radiotelemetry. Our results illustrate an increased number of sleep 
transitions and decreased wake duration in Cav 2.3
+/+
 mice, thus confirming the Cav2.3 
R-type Ca
2+
 channel to be exclusively involved sleep regulation.  
Previously, Cav 2.3
-/-
 mice were also reported to exhibit absence seizure susceptibility 
indicating the Cav2.3 R-type Ca
2+
 channel to be related to epileptogenesis. Alterations in 
brain rhythmicity as well as seizure susceptibility can be promoted by Aß plaque 
accumulation as occurring in Alzheimer’s Disease (AD). Recent studies in mouse 
models of familial AD (FAD) depict changes in protein synthesis of ß-site APP cleaving 
enzyme 1 (BACE1) to be ultimately responsible for increased generation of Aß plaques. 
In this regard elevated translation of BACE1 has been associated with increased 
phosphorylation of the eukaryotic translation initiation factor 2 alpha (elF2α) at serine 
51. This fact leads to the question, if decreased levels of phosphorylated elF2α could 
prevent 5xFAD mice from exhibiting enhanced amyloidogenesis and increased amount 
of seizure activity and therefore delaying cognitive decline. Hence, we analyzed 
possible preventative effects of elF2α on epileptogenesis in Alzheimer’s disease by 
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crossing 5xFAD mice with an elF2αS51A knock-in mouse line, in which elF2α cannot be 
phosphorylated on the mutant allele according to substitution of serine by alanine at 
position 51. Our results depict elF2αS51A to have a limited rescue effect on motor and 
cognitive deficits in 5XFAD mice. Hippocampal alterations were in line with 
electrophysiological findings depicting non-convulsive seizure activity in 5XFAD mice 
carrying the elF2αS51A allele. Furthermore, we investigated the effects of seizure activity 
on the muscarinic signaling cascade in the 5XFAD mice. Our results demonstrate that 
enhanced muscarinic signalling is directly linked to neuronal dysrhythmia and increased 
amount of atropine sensitive type II theta in 5XFAD mice that might be understood as a 
compensatory mechanism according to an imbalanced neuronal system in AD. 
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Abbreviations 
 
 
 
ACE                nucleus of central amygdala 
Aß amyloid-ß  
AD Alzheimer’s disease 
AFC                 absolute fold change 
ATF4              activating transcription factor 4 
APP amyloid precursor protein 
BACE1 ß-site APP cleaving enzyme 1 
ChAT              rabbit anti-choline acetyltransferase 
cGMP             guanosine cyclic monophosphate 
CNG               cyclic nucleotide-gated ion channel 
CTF                 COOH-terminal fragment 
DAB               diaminobenzidine 
DAG                  diacylglycerol 
EEG                electroencephalogram 
elf2α                eukaryotic translation initiation factor 2α 
FAD familial Alzheimer’s disease 
GABAA                gamma-aminobutyric acid 
hAPP               human amyloid precursor protein 
HCN hyperpolarization-activated, cyclic nucleotide-gated cation (channels)  
HVA high-voltage activated 
IP3                  inositol triphosphate  
KO                  knock-out 
LIA                 large irregular activity 
LTCS             low-threshold Ca
2+ 
spike 
LTP                 long-term potentiation 
LVA               low-voltage activated 
M1                  primary motor cortex 
M1/M3           muscarinic M1/M3 receptor 
mGLUR1       metabotropic glutamate receptors group I 
MS-DBB        medial septum/diagonal band of Broca          
NFT neurofibrillary tangles 
NREM            non-rapid eye movement (sleep)  
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PKCδ              protein kinase C delta type  
PLCß1            phospholipase C beta type 
PSEN1 presenilin 1 
PS                   paradoxical sleep 
PVDF             polyvinylidene difluoride  
qPCR              quantitative Real-time PCR  
REM              rapid-eye movement (sleep)  
RTN               reticular thalamic nucleus  
sAHP              slow afterhyperpolarisation 
SK2                small-conductance Ca
2+
-activated K
+ 
channel type 2 
SWD              spike-wave discharge 
SWS               slow-wave sleep 
TBS                 tris-buffered saline  
TC                   thalamocortical system 
TLE                 temporal lobe epilepsy 
VDB                diagonal band of Broca                                                                                 
VGCC            voltage-gated Ca
2+ 
channels 
WT wild-type 
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1. Introduction 
1.1 Rhythms of the Brain-Molecular Dissection of Theta Activity  
In our everyday life communication and interaction with our fellow men seems to be 
self-evidently indispensable. However, for living and adapting to a constantly changing 
environment, we rely on the ability to process information from distinct physical 
dimensions simultaneously. In other words, mastering the complex processing of 
ongoing behaviour requires high efficiency of neuronal networks. Over the recent years, 
investigators were making an effort to enrich our knowledge of how populations of 
neurons contribute to cognitive functions by analysing highly synchronized activity 
pattern, so-called oscillations. In this regard, oscillations provide the 
electrophysiological mechanism for coordination of brain regions by streaming the 
activity of neuronal ensembles to intentional behaviour. However, the detailed 
mechanisms still remain poorly understood. Recently, it could be shown that the 
hippocampus plays an important role in central rhythmicity. Being a part of the limbic 
system combining emotional and spatial information (Bird and Burgess, 2008), the 
hippocampus exhibits different classes of oscillations, which are connected to particular 
cognitive states (Buzsaki et al., 1983; Colgin, 2013). Thereby, large irregular activity 
(LIA) containing sharp waves, marks behavioural automatisms on the one hand. On the 
other hand the hippocampus exhibits rhythmic pattern of high amplitude emerging as 
local field potentials from the the hippocampal CA3 and the stratum lacunosum-
moleculare of the CA1 region occurring at a frequency range of 4-7 Hz (Buzsaki, 2002; 
Kahana et al., 1999; Vanderwolf, 1969). These hippocampal theta oscillations are 
strongly involved in memory consolidation during rapid eye movement sleep (REM), 
information encoding and exploratory behaviour (Colgin, 2013; Hangya et al., 2009; 
Kahana et al., 1999; Montgomery and Buzsaki, 2007). Consequently, they can be seen 
as the “online state” of the hippocampus. Theta activity and can be pharmacologically 
evoked by stimulation of cholinergic und glutamanergic pathways. According to the 
sensitivity to certain drug types, theta oscillations can be divided into two different 
subgroups, type I and type II theta that are also related to certain behavioural modes of 
the hippocampus (Buzsaki, 2002). Thereby, type I theta or atropine resistant theta 
requires activation through metabotropic glutamate receptors group I (mGluR1) and 
remains pharmacologically unaffected to anticholinergic drugs like atropine (Buzsaki, 
2002). Atropine resistant theta is physiologically present during locomotion and REM 
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sleep (Vanderwolf, 1969; Winson, 1974). In contrast, type II theta or atropine sensitive 
theta occurs during immobility and can be experimentally induced by urethane or 
specific muscarinic agonists, such as pilocarpine, arecoline or oxotremorine (Buzsaki, 
2002). At first glance the pharmacological dissection of theta activity might seem to be 
trivial. However, it indicates that theta oscillations can be entrained by different 
excitatory sources in absence of either cholinergic or glutamanergic inputs. In this 
regard, it has been a question of debate whether hippocampal theta genesis arrives from 
extrinsic input from the medial septum/diagonal band of Broca (MS-DBB) or can be 
intrinsically elicited by horizontal cell-interneuron interconnectivity via 
hyperpolarization-activated  and cyclic nucleotide-gated  nonselective cation (HCN) 
channels (Goutagny et al., 2008; Hangya et al., 2009; Manseau et al., 2008). HCN 
channels interact together with small-conductance Ca
2+
-activated K
+ 
channel type 2 
(SK2) channels as a functional unit and are responsible for a reprimed Ca
2+ 
current 
mediated burst cycle. Furthermore, preliminary studies demonstrate that on the 
molecular level theta oscillations are mediated by voltage-gated Ca
2+ 
channels, e.g. 
Cav2.3 R-type Ca
2+ 
channels via intracellular muscarinic cascades (Shin et al., 2006; 
Shin, 2006). Activation of Gaq/11 coupled  muscarinic M1/M3 receptors is capable to 
enhance R-type currents in pyramidal neurons of rat hippocampal CA1 region via the 
generation of diacylglycerol (DAG) and inositol triphosphate (IP3) followed by 
phospholipase C beta1 (PLCß1) and phosphokinase C delta (PKCδ) activation (Tai et 
al., 2006) while leaving T-type Ca
2+ 
currents unaffected. These findings were recently 
supported by the fact that deletion of PLCß1 leads to absence of type II theta (Shin et 
al., 2005) underlying the functional importance of Cav 2.3 Ca
2+
 channels and the 
muscarinic pathway in theta genesis. Although the final signaling pathway of still 
remains unrevealed, it is not surprising that after muscarinic stimulation enhanced 
intracellular cytosolic Ca
2+ 
levels mediated by Cav2.3 R-type Ca
2+ 
channels can also 
implicate the activation of CNG channels through increased guanosine cyclic 
monophosphate (cGMP) levels. Consequently, CNG channels contribute to prolonged 
membrane potentials with pronounced bursting, that is responsible for exhibition of 
epileptiform activity (Tai et al., 2006). Hence, Cav2.3 R-type Ca
2+ 
currents followed by 
the activation of muscarinic receptors can elite both, theta as well as seizure activity. 
Due to this fact, it is indispensable to take secondary effects and functions of the Cav2.3 
R-type Ca
2+ 
channel into account to provide its comprehensive role in neuronal network 
functioning sufficiently.  
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1.2 The Cav2.3 R-type Ca
2+ 
Channel in Rodent Sleep Architecture 
To get a global view of the functional role of the voltage-gated calcium channels it is 
necessary to look closer at intrinsic mechanisms of single neurons and propensity of 
coupled neuronal networks exhibiting coherent oscillatory states at a variety of spatial 
extent and frequency. Modulatory processes within neuronal circuits indicate dynamical 
changes of oscillations providing clues of one or many entire neuronal systems at 
particular cognitive states. Indeed, it was recently proven that Cav2.3 R-type Ca
2+ 
channels are key regulators in neuronal excitability by regulating internal Ca
2+
 levels 
(Tao et al., 2008). Increase of internal Ca
2+
 levels finally results in afterdepolarisations 
(Kuzmiski et al., 2005; Metz et al., 2005) and long-lasting plateau potentials via 
activation of Cyclic nucleotide-gated ion channels (CNG) (Kuzmiski and MacVicar, 
2001) that can trigger absence slow wave discharges (SWDs) in the hippocampus 
(Lakaye et al., 2002). The extraordinary role of Cav2.3 R-type Ca
2+ 
channels are 
furthermore supported by the observation that administration of carbachol leads to an 
enhanced E/R type dependent spiking of CA1 neurons while other channel activity is 
depressed (Gahwiler and Brown, 1987; Toselli et al., 1989). Cav2.3 R-type Ca
2+ 
channels are dominantly expressed in dendrits and soma of CA1 neurons but can also be 
found in the thalamocortical network (Day et al., 1996; Westenbroek et al., 1995). 
Taking the fact into consideration that Cav2.3 R-type Ca
2+
 channels are differentially 
distributed throughout neuronal entities but are always regulated via muscarinic 
receptors as a biochemical unit, it is fear to assume that Cav2.3 R-type Ca
2+ 
channels do 
not only shape up as key players in hippocampal seizure propagation and 
epileptogenesis (Lakaye et al., 2002) but might be also crucially involved in mediating 
thalamocortical rhythmicity as well. By simplifying thalamic rhythmicity, the 
thalamocortical system (TC) is composed of two different classes of neuronal 
population, the Reticular thalamic nucleus (RTN) neurons and relay cells, which are 
capable of switching between different modes of action while receiving input from 
cortical regions and extrathalamical structures. During high stages of vigilance thalamic 
neurons exhibit the tonic mode of action at slightly depolarised membrane potentials. 
Thereby, tonic neuronal activity within thalamic relay cells is due to activating input 
from deeper brainstem structures and simultaneous inhibition of RTN neurons. These 
processing mechanisms of peripheral information are finally encoded as action 
potentials to the cortex during wake state. With decreased input from 
extrathalamocortical structures sensory gating is abolished and both, relay and RTN 
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neurons, shift to a rebound burst firing mode of action. On a cellular level different 
stages of vigilance are linked to activation of specific Ca2+ channels. Previously, it was 
shown, that low-voltage activated (LVA) Cav3 T-type Ca
2+
 channels which are 
expressed in thalamic relay cells have been related to thalamic rebound burst firing and 
the generation of non-rapid eye movement sleep (NREM sleep) (Contreras, 2006). In 
contrast, burst activity is accomplished by Cav2.3 Ca
2+ channels that are highly 
expressed in the RTN. Cav2.3 mediated Ca
2+ influx into RTN neurons triggers potassium 
release through activation of a small conductance Ca2+-activated potassium channels 
(SK2). Consequently, SK-mediated K currents repolarize RTN neurons causing 
repriming of LVA T-type Ca2+ channels and activation of HCN channels. As a result of 
the subsequent membrane depolarisation, a low-threshold Ca2+ spike (LTCS) is 
generated leading to Cav2.3 Ca
2+ channel activation that initiates SK channel opening in 
a cyclic manner. By the periodic activation of the individual ion channel entities, burst 
cycles in the RTN are mediated resulting in SWS delta oscillations (Zaman et al., 2011). 
In accordance to these findings, it was also reported that Cav2.3
-/- mice exhibit absence 
seizure susceptibility and altered spike-wave discharges by effecting thalamocortical 
hyperoscillations similar to seizure propagation in the hippocampus (Weiergraber et al., 
2008). Hence, it can be strongly suggested, that Cav2.3 R-type Ca
2+ 
channels are 
fundamentally pertinent to thalamocortical rhythmicity 
 
1.3 The functional Role of Theta Activity in Alzheimer`s Disease 
How can oscillations contribute to a better understanding of cognition and how might 
they serve as potential biomarkers for the diagnosis of cognitive decline even before the 
onset of neurodegeneration? To answer these questions it is necessary to investigate the 
changes and modifications of oscillatory activity, particularly of theta rhythms, as well 
as their potential relevance to progressive pathophysiology of Alzheimer`s Disease 
(AD). AD is the most common, irreversible form of dementia that is associated with 
extensive synaptic loss and disruption of learning and memory skills (Selkoe and 
Schenk, 2003). Histologically, it is characterized by amyloid-ß plaques (Aß plaques) 
and neurofibrillary tangles (NFT) typically occurring in specific brain regions like the 
hippocampus (Ashe, 2001). Nowadays, it is believed that soluble Aß assemblies which 
contribute to neurotoxic plaque formation mediating negative effects on learning and 
memory. However, the whole mechanism behind the disease still remains unclear. 
Atropine sensitive type II theta is liable to age-dependent neuronal degeneration 
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resulting in structural reorganization of networks and cognitive decline. Although type 
II theta is consistently decreased at old age, it could be shown that activation of the 
muscarinic pathway is able to retard neuronal disruption as a result overexpressed 
amyloid beta formation in AD (Buttini et al., 2002; Kar et al., 2004; Kar and Quirion, 
2004). Hence, theta activity and its underlying molecular structures can contribute to 
preservation of physiological network functioning. In this regard, transgenic mouse 
models carrying the mutated human amyloid precursor protein (APP) and presenilin1 
(PSEN1) gene, recapitulate a huge range of AD-like phenotypes, attempting to promote 
our understanding of hippocampal function. In this regard, 5XFAD mice (Tg6799 line, 
Jackson Laboratories) carry five familial AD mutations, which at high levels of 
expression have been proved to show the most aggressive phenotype. Therefore 5XFAD 
mice are widely used to especially mimic histological and cognitive hallmarks of early-
onset AD. 5XFAD mice display accumulation of intraneuronal Aß42 already at the age 
of 1.5 months followed by massive neuronal loss (Moon et al., 2012; Oakley et al., 
2006). Synaptic degeneration and spatial learning deficits can be detected by around 4 
months of age caused be rapidly increasing amount of plaques which spread throughout 
the hippocampal formation and finally reaching and disrupting cortical areas (Kimura et 
al., 2007; Oakley et al., 2006) . Recently, it was illustrated that impaired LTP in 5XFAD 
mice (Crouzin et al., 2013) is linked to the expression of the protein synthesis of β-site 
APP cleaving enzyme 1 (BACE1) that is ultimately required for the generation of  Aß 
plaques by cleaving the APP to produce Aß42 peptides (Ohno et al., 2006; Zhao et al., 
2007). Concerning this, it has been a question of debate how disruption of the 
hippocampal network caused by Aß plaque accumulations can elicit pharmacologically 
unprovoked seizures as being present in patients with AD at high prevalence in 
comparison to elderly individuals (Mendez and Lim, 2003). Although pharmokokinetic 
changes in neuronal networks occur with aging and may contribute to the incidence of 
epilepsy in AD, previous studies clearly depict that high levels of Aß are sufficient to 
elicit seizures in mice expressing human APP (hAPP) (Palop et al., 2007; Palop and 
Mucke, 2009; Palop and Mucke, 2010). Furthermore, it could be demonstrated that 
enhanced translation of BACE1 protease causes increased numbers of Aß plaques that 
lead to a reorganisation of neuronal networks, finally resulting in an imbalance of 
excitation and inhibition. This imbalance can produced hyperexcitability states in the 
hippocampus and finally facilitate seizures (Metz et al., 2005). Hence, 5XFAD mouse 
model exhibit seizure like activity. Because the translation of BACE1 is directly linked 
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to the phosphorylation of eukaryotic translation initiation factor 2 alpha (elF2α), down-
regulation of this factor could lead to delayed cognitive decline in AD and preserve 
5XFAD mice from developing epileptiform activity. Interestingly, cognitive deficits of 
these models can be improved by the reduction of endogenous tau protein (Palop and 
Mucke, 2009; Roberson et al., 2007). In this regard, previous studies give also evidence 
that amelioration of cognitive skills can be furthermore achieved by theta activity. By 
comparing wakefulness and REM sleep in which seizures are less frequent to other 
functional conditions of the hippocampus, it becomes obvious that theta activity can 
preserve neuronal networks from increased seizuring (Colom et al., 2005; Colom, 2006; 
Miller et al., 1994). The relationship between theta activity and the occurrence of 
seizures in AD can be explained by the activation of cholinergic and glutaminergic 
pathways that are required for both oscillation pattern (Gutierrez-Lerma et al., 2013; 
Palhalmi et al., 2004; Reich et al., 2005). Unlike the previous opinion that Aß peptides 
lead to network disruption and changes in theta activity through a general cellular 
mechanism, it could be shown that type I and II theta are differentially altered by certain 
Aß peptide species providing evidence for a specific cellular mechanism (Gutierrez-
Lerma et al., 2013) by which theta activity can be shaped. Alterations in theta 
rhythmicity can either result in increased (Babiloni et al., 2007; Blanchet, 2003; 
Cummins et al., 2008; Pena-Ortega and Bernal-Pedraza, 2012) or reduced (Cummins et 
al., 2008) amount of theta activity according to the present stage of cognitive decline in 
specific mouse models of AD. For this reason it is still challenging to link changes in 
theta activity to the dynamic neurobiology of AD. Furthermore, it could be also 
demonstrated that over-production of Aß does not necessarily need to be related to over-
excitation of the hippocampal network. Recent studies by Goutagny et al., 2013 
demonstrated that slight changes in the hippocampal theta activity might occur much 
earlier than recently suggested. Altered theta rhythmicity can even become obvious 
before histological hallmarks of AD like an advanced manifestation of Aß accumulation 
are fully apparent (Goutagny et al., 2013; Goutagny and Krantic, 2013). These findings 
could facilitate our understanding of theta oscillations as suitable predictors for 
especially early-onset familial AD in future.  
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1.4. Aim of the study 
The present thesis was aimed to dissect the functional role of the voltage-gated Cav2.3 
R-type Ca2+ channel in sleep architecture and seizure susceptibility in the 5XFAD 
mouse model of familial AD.  
 
The first study was aimed to declare how Cav2.3 R-type Ca
2+ 
channels are involved in 
regulating thalamocortical circuits, thus controlling vigilance and mediating SWS. 
Motivated by previous results showing that Cav2.3 R-type Ca
2+ 
channels are responsible 
for initiation of thalamic rebound burst firing as required for SWS, we investigated 
Cav2.3 R-type Ca
2+ 
channels in spontaneous and artificial, urethane induced sleep in 
Cav2.3
+/+
 mice and Cav2.3
-/-
 mice using implantable video-EEG radiotelemetry. By 
preforming time-frequency analysis, we determine alterations in sleep architecture under 
physiological conditions and sleep deprivation. Furthermore, we used quantitative 
Realtime PCR to depict any possible changes in thalamic Ca
2+ 
channel expression.   
 
In the second study we investigated the functional role of non-phoshorylated elF2α 
allele (elF2αS51A) and its possible preventative effect on AD progression and 
epileptiform activity in 5XFAD mice. Phosphorylated form of elF2α is closely related to 
the BACE1 synthesis which is responsible for Aß plaque formation, finally leading to 
elevated seizure susceptibility. Here, we combined electrophysiological together with 
molecular and behavioural approaches in 5XFAD, 5XFAD- elF2α S51A/+, elF2α S51A/+ 
and wild type mice to verify, if elF2αS51A could improve cognitive performance and 
delay cognitive decline. 
In the third study we attempt to illustrate the functional interdependence between 
hippocampal theta activity and seizure susceptibility in the 5XFAD mouse model. To 
answer the question in what extent hippocampal theta oscillations are altered and how 
seizure activity might contribute to enhanced cognitive decline, we investigated 
transcriptional alterations in relation to the EEG phenotype of 5XFAD mice. 
20 
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Study Objectives: Voltage-gated Ca
2+ 
channels (VGCCs) are key elements in 
mediating thalamocortical rhythmicity. Low-voltage activated (LVA) Cav3 T-type 
Ca
2+ 
channels have been related to thalamic rebound burst firing and to generation of 
non-rapid eye movement (NREM) sleep. High-voltage activated (HVA) Cav1 L-type 
Ca
2+ 
channels, on the opposite, favor the tonic mode of action associated with higher 
levels of vigilance. However, the role of the  HVA  Non-L-type  Cav2.3  Ca
2+ 
channels,  which  are  predominately  expressed  in  the reticular thalamic nucleus 
(RTN), still remains unclear. Recently, Cav2.3
-/-
mice were reported to exhibit altered 
spike-wave discharge / absence seizure susceptibility supported by the observation that 
Cav2.3 mediated Ca
2+ 
influx into RTN neurons can trigger small-conductance Ca
2+ 
activated K
+
-channel type 2 (SK2) currents capable of maintaining thalamic burst 
activity. Based on these studies we investigated the role of Cav2.3 R-type Ca
2+ 
channels in rodent sleep. 
Methods: The role of Cav2.3 Ca
2+ 
channels was analyzed in Cav2.3
-/- 
mice and 
controls in both spontaneous and artificial, urethane induced sleep, using implantable 
video-EEG radiotelemetry. Data were analyzed for alterations in sleep architecture 
using sleep staging software and time-frequency analysis. 
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Results: Cav2.3 deficient mice exhibited reduced wake duration and increased 
slow-wave sleep (SWS). Whereas mean sleep stage durations remained unchanged, the 
total number of slow-wave sleep epochs was increased in Cav2.3
-/-
mice. Additional 
changes were observed for sleep stage transitions and EEG amplitudes. Furthermore, 
urethane-induced slow-wave sleep mimicked spontaneous sleep results obtained from 
Cav2.3 deficient mice. Quantitative Real-time PCR did not reveal changes in thalamic 
Cav3 T-type Ca
2+ 
channel expression. The detailed mechanisms of SWS increase in 
Cav2.3
-/-
mice remain to be determined. 
Conclusions: Cav2.3 R-type Ca
2+ 
channels in the thalamocortical loop and 
extrathalamocortical circuitries substantially regulate rodent sleep architecture thus 
representing a novel potential target for pharmacological treatment of sleep disorders in 
the future. 
 
Key words: rapid eye movement (REM), slow-wave sleep (SWS), thalamocortical 
circuitry, vigilance
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Introduction 
Voltage-gated Ca
2+ 
channels (VGCCs) play key roles in numerous physiological 
processes, including excitation-contraction and excitation-secretion coupling,
 
neurotransmission
 
and regulation of gene expression (Bers and Weber, 2002; Catterall, 
2011; Hofmann et al., 1999; Yang and Berggren, 2005).
 
Both high-voltage activated 
(HVA) L-type and low-voltage- activated (LVA) T-type Ca
2+ 
channels were reported to 
be involved in the regulation of mammalian sleep, due to their functional involvement 
in thalamocortical and extrathalamocortical rhythmicity (Catterall et al., 2003; Catterall 
et al., 2005; Jones, 2002; Lopez-Bendito and Molnar, 2003).
 
Thalamocortical relay 
neurons and reticular thalamic nucleus (RTN) cells harbour the capability to switch 
between different functional modes, i.e. the tonic, intermediate and burst mode of 
action. The depolarisation of thalamic relay cells, at least in part, is due to the activating 
input of deeper brainstem structures, e.g. the reticular formation, and concomitant 
disinhibition of RTN neurons that project to ventrobasal thalamic relay cells. The tonic 
firing mode is characteristic of stages of high vigilance. With decreasing activity from 
deeper activating brain regions, thalamic relay cells re- and hyperpolarize. They pass 
through the intermediate mode and finally exhibit the rebound burst firing mode of 
action (Beenhakker and Huguenard, 2009; Llinas and Steriade, 2006; Steriade, 2005).
 
A 
complex armamentarium of voltage- and ligand-gated ion channels including LVA 
Cav3.1-3.3 T-type Ca
2+ 
channels, hyperpolarization and cyclic-nucleotide gated, non-
specific cation channels, i.e. HCN2 and HCN4, can trigger low-threshold calcium 
spikes (LTCSs) with superimposed bursts of conventional Na
+
/K
+ 
action potentials 
(Llinas and Steriade, 2006).
  
Termination of this cycle is mediated by both voltage- and 
Ca
2+ 
activated current enties, e.g. IA mediated and Ik(Ca).
 
Rebound burst firing in the 
thalamocortical circuitry is typical for stages of low vigilance, including slow-wave 
sleep (SWS). In addition, enhanced oscillatory discharges resulting in rebound burst 
firing of thalamic relay neurons and RTN cells were shown to play a crucial role in the 
etiopathogenesis of absence epilepsy (Shin et al., 2006; Shin, 2006).
 
Voltage-gated Ca
2+ 
channels turned out to be of major relevance in the etiopathogenesis of absence epilepsy 
and the physiology of sleep due to their unique electrophysiological properties and 
cellular distribution (Anderson et al., 2005; Astori et al., 2011; Cheong and Shin, 2013; 
Kim et al., 2001; Lee et al., 2004; Lee and Shin, 2007; Petrenko et al., 2007; Siwek et 
al., 2012; Talley et al., 2000).
 
Interestingly, recent studies demonstrate that the HVA 
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Non-L-type Cav2.3 Ca
2+ 
channel plays an important role in thalamocortical rhythmicity 
(Talley et al., 2000; Weiergraber et al., 2006; Weiergraber et al., 2008; Zaman et al., 
2011).
 
 Cav2.3 R-type Ca
2+ 
channels are expressed in GABAergic interneurons of the 
cortex and the RTN (Talley et al., 2000; Weiergraber et al., 2006; Weiergraber et al., 
2008).
 
Initial analysis of absence seizure susceptibility in Cav2.3
-/- 
and control animals 
revealed that Cav2.3 Ca
2+ 
channel affects thalamocortical hyperoscillation and absence 
seizure architecture (Talley et al., 2000; Weiergraber et al., 2008).
 
 
In accordance to 
reports on the absence-preventive effect of Bay K8644- enhanced HVA Ca
2+ 
current, 
we speculated that HVA Non-L-type Cav2.3 channels might also favor the tonic mode 
of action (Talley et al., 2000; Weiergraber et al., 2008). Lately, the role of Cav2.3 R-type 
Ca
2+ 
channels in thalamocortical rhythmicity was elaborated in detail on the thalamic 
level by Zaman et al. (Zaman et al., 2011) using a combination of in-vitro and in-vivo 
methods. Injection of a hyperpolarizing current in a brain slice approach was capable of 
triggering a low-threshold Ca
2+ 
spike with superimposed Na
+ 
bursts in RTN neurons 
from Cav2.3
-/- 
mice. Interestingly, subsequent oscillatory burst charges were strongly 
suppressed and slow afterhyperpolarisations (sAHP) reduced. About 51% of HVA Ca
2+ 
current in RTN neurons turned out to be SNX-482 sensitive and could be dedicated to 
Cav2.3 R-type Ca
2+ 
channels. Furthermore, Cav2.3 mediated Ca
2+ 
influx was shown to 
interfere with voltage-insensitive SK2 channels that contribute to the generation of Ca
2+
-
dependent sAHP. Zaman et al. (Zaman et al., 2011)
 
argued that T-type Ca
2+ 
channels 
per se are not sufficient to maintain Ca
2+ 
levels that can trigger sAHP, the latter 
however is a prerequisite for repriming T-type Ca
2+ 
channels and sustained rebound 
bursting. Consequently, Cav2.3
-/- 
mice display reduced RTN oscillatory activity and 
reduced absence seizure susceptibility. Hence, we speculated that Cav2.3 R-type Ca
2+ 
channels might also affect thalamocortical network oscillation relevant for SWS and 
overall sleep architecture. To test this hypothesis, we performed analysis of spontaneous 
sleep, sleep deprivation and pharmacologically induced sleep in Cav2.3
-/- 
mice and 
controls using implantable video-EEG radiotelemetry. Our data provide evidence that 
Cav2.3 R-type channels are functionally relevant for the generation of SWS and 
modulation of sleep architecture in mice. 
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Materials and Methods 
Study animals 
Cav2.3
+/- 
embryos (kindly provided by Richard J. Miller, Department of Neurobiology 
Pharmacology, and Physiology, The University of Chicago, Chicago (Wilson et al., 
2000) were rederived with C57BL/6J mice and maintained with random intra-strain 
mating obtaining all genotypes. Five Cav2.3
+/+ 
(mean body weight: 27.58 ± 0.98 g, 
mean age: 13.49 ± 0.51 wk s ,  all controls) and five Cav2.3
-/-
mice (mean body 
weight: 31.98 ± 0.63 g, mean age: 17.74 ± 0.83 wks, all ♂) have been used for 
spontaneous and drug-induced sleep analysis. Three Cav2.3
+/+ 
(mean body weight: 
29.50 ± 0.66 g, mean age: 13.60 ± 1.17 wks, all controls) and three Cav2.3
-/- 
mice 
(mean body weight: 31.80 ± 1.49 g, mean age: 12.60 ± 0.19 wks, all ♂) were used for 
sleep deprivation experiments. All mice were housed in groups of 3-4 inclear Macrolon 
cages type II with ad libitum access to drinking water and standard food pellets. Using 
ventilated cabinets (Model 9AV125P, Techniplast, Germany), mice were maintained at 
a temperature of 21 ± 2 °C, 50 – 60% relative humidity, and on a conventional 12 hrs 
light/dark cyclewith the light cycle beginning at 5:00 AM for spontaneous and drug-
induced sleep studies. For sleep deprivation experiments a 12 hrs light/dark cycle with 
the light cycle starting at 8:00 AM was implemented. The animals were strictly adapted 
to this circadian pattern for 14 days preceding subsequent experimentation. All animal 
procedures were performed according to guidelines of the German Council on Animal 
Care and all protocols were approved by the local institutional and national committee 
on animal care. 
 
Radiotelemetric EEG electrode implantation and EEG recordings 
Mice were anesthetized using ketamine/xylazine (100/10 mg/kg ip.) and the 
radiotelemetry transmitter (TL11M2-F20-EET 2-channel transmitter, Data Science 
International (DSI), specifications: weigth 3.9 g, volume 1.9 cc, input voltage range  ± 
1.25 mV, channel bandwidth 1 - 50 Hz) was implanted into a subcutaneous pouch on 
the back of the animals. The differential EEG electrode was stereotaxically positioned 
using a computerized 3D stereotaxic StereoDrive
®
(Neurostar, Germany) at the 
following coordinates: (+)-lead: bregma, -1.5 mm; mediolateral, -3.0 mm (right 
hemisphere); dorsoventral, 0.0 mm (target region: SB1 barrel field cortex). The 
reference electrode, i.e. (-)-lead was positioned on the cerebellar cortex: bregma, -6.0 
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mm; mediolateral, 0.0 mm; dorsoventral, 0.0 mm (Supplemental Fig. 1). Electrodes 
were fixed using glas ionomer cement and the scalp was closed using over and over 
sutures (Ethilon, 6-0). Electrodes of the second transmitter channel were fixed on the 
nuchal muscle at a distance of 5 mm and used for EMG recording (Supplemental Fig. 
1). A detailed description of the procedure is given in Weiergräber et al., 2005.
  
For 
postoperative pain management animals were administered carprofen (5 mg/kg sc.). 
Animals were allowed to recover for 10 days prior to subsequent recordings. This 
recovery period is based on the observation that 10 days post-surgery no difference in 
physiological parameters between transmitter implanted, non-implanted and sham-
operated animals could be detected(Kramer and Kinter, 2003). 
 
Spontaneous sleep recordings 
Following a 10 day recovery period, video-EEGs were recorded 48 hrs continuously 
using the Dataquest ART 4.2 software (DSI) at a sampling rate of 500 Hz with no a 
priori filter cut-off. For detailed evaluation of sleep architecture, radiotelemetric EEG 
data were processed using the Neuroscore 2.1 automated sleep scoring module (DSI). 
Sleep deprivation 
Following a 10 day recovery period after transmitter implantation, mice were sleep 
deprived for 6 hrs starting at 8:00 AM till 2:00 PM. During sleep deprivation period 
animals were aroused by tapping on the cage and applying tactile stimuli, i.e. gently 
touching them with a soft brush, for 5 min at an interval of 30 min (Patti et al., 2010).
 
Video-EEGs were recorded prior to, during and post sleep deprivation using the 
Dataquest ART 4.2 software (DSI) at a sampling rate of 500 Hz with no a priori filter 
cut-off. For detailed evaluation of sleep architecture, radiotelemetric EEG data were 
processed using the Neuroscore 2.1 automated sleep scoring module (DSI). 
Drugs und pharmacological injection experiments 
Urethane was purchased from Sigma (Germany) and freshly dissolved in 0.9% NaCl 
prior to the injection. Cav2.3
+/+ 
and Cav2.3
-/-
mice were injected 800 mg/kg body weight 
ip. at day 13 post transmitter implantation to pharmacologically induce slow-wave 
sleep. EEGs were recorded and analyzed for 8 hrs after urethane injection. 
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Analysis of sleep architecture 
Sleep analyses and calculations were performed using Neuroscore 2.1 rodent sleep 
scoring software (DSI). Three vigilance states, i.e. the wake state (quiet and active), the 
non-rapid eyemovement (NREM) sleep including slow wave sleep (SWS) 1 and SWS 2 
and rapid eye movement (REM) sleep (paradoxical sleep, PS) were determined for 10 s 
epochs. Recording segments containing EEG or EMG artefacts were automatically 
excluded from analysis. The EMG threshold as an important setting of the automated 
sleep scoring software was adapted based on the individual level of ECG contamination 
in the EMG recording. EEG power spectra were computed for 10 s epochs using fast 
Fourier transformation (sampling rate 250 Hz, Hamming window) and analyzed for 
selected frequency bands (delta: 0.5 - 4 Hz, theta: 4 - 8 Hz, alpha: 8 - 12 Hz, beta 12 - 
24 Hz and gamma 24 - 50 Hz). 
EEG data analysis 
Complex EEG analysis was performed for spontaneous 48 hrs sleep recordings at a 
sampling rate of 500 Hz. In addition, urethane induced artificial SWS was analyzed 
using 60 min baseline recordings as control and a 180 min recording period following 
drug exposure. EEG analysis was performed using the complex Morlet wavelet to 
calculate both frequency and amplitude of oscillations. The complex Morlet wavelet is 
defined by Ψ(x) = (πb)(–1/2) exp(2iπcx)exp(-x2/b), with b representing the bandwidth 
parameter, c the center frequency and i the imaginary unit (Muller et al., 2012)
 
. This 
wavelet has often been applied in literature to study EEG data as it guarantees optimal 
resolution in both frequency and time (Kronland-Martinet et al., 1987; Montgomery and 
Buzsaki, 2007).
 
In our study the bandwidth parameter and center frequency were both 
set to 3 in order to particularly weight the frequency resolution to distinguish frequency 
differences on the 0.1 Hz level, but not to neglect a sufficient time resolution. EEG data 
were analyzed in the frequency range of 0.5 - 12 Hz with a step size of 0.1 Hz, thus 
including the typical delta, theta and alpha frequency ranges. For computational reasons, 
raw EEG data were segregated into 60 min segments. According to segment duration in 
the Neuroscore
® 
sleep module, mean amplitudes for the three frequency bands (delta: 
0.5 – 4 Hz; theta: 4 – 8 Hz; alpha: 8 – 12 Hz) were calculated for 10 s non overlapping 
segments. Every segment was assigned to one of the four vigilance stages, i.e. wake, PS, 
SWS 1, SWS2 according to the Neuroscore
® 
sleep module. Calculated frequency-
specific amplitudes were averaged for distinct wake/sleep stages and analyzed for both 
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the entire 48 hrs recording period and the light/dark cycle.  Mean amplitudes for the 
three frequency bands were statistically analyzed. All calculations were done using 
custom-made programs in Matlab
® 
(The MathWorks Inc., Version R2012b). 
 
Quantitative Real-time PCR (qPCR) 
To elaborate potential compensating effects of Cav3.1, Cav3.2 and Cav3.3 T-type Ca
2+ 
channels in Cav2.3
-/- 
mice that might account for altered sleep architecture, the 
expression levels of Cav3 Ca
2+ 
channels were analyzed using quantitative Real-time 
PCR (qPCR). Total RNA was extracted from the thalamus of three male mice from each 
genotype (Cav2.3
+/+
, controls, mean age: 15.86 ± 0.08 wks; Cav2.3
+/-
, all 15 wks; Cav2.3
-
/-
, all 15 wks) using RNeasy Lipid Tissue Mini Kit (Qiagen). The cDNA synthesis was 
carried out using anchored-oligo(dt)18 and hexamer primer in a two-step RT-PCR 
approach (Transcriptor First Strand cDNA Synthesis Kit, Qiagen) and qPCR reaction 
protocol was based on Light Cycler 480 SYBR Green I Master (Roche). The qPCR was 
performed in a Light Cycler 480 System (Roche) thermocycler. The following cycler 
protocol was used for all primer pairs according to 58,59 (Tab. 1): 95°C (10 min, pre-
incubation step); 95°C (10s, melting step); 60°C (20s, annealing step); 72°C (30 s, 
extension step), 35 cycles.  
 
 
 
 
The specificity of the amplification was checked by melting curve analysis and the 
products were identified by electrophoresis. Deionized, nuclease-free water (no cDNA) 
and total RNA samples (without RT) were used as controls. The Ct-values (cycle 
threshold) were calculated using the LightCycler 480 System software. Fold changes 
(FC) of Cav3.1, Cav3.2 and Cav3.3 gene expression in Cav2.3
+/-
and Cav2.3
-/- 
mice related 
to controls were calculated according to Schmittgen and Livak (2008). 
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Statistical analysis 
Statistical analyses concerning sleep architecture, amplitudes, comparisons between 
groups, also regarding different frequency bands were done with IBM
® 
SPSS
® 
21 (IBM, 
Inc.). The Kolmogorov–Smirnov approach was used to test for normal distributions. 
The two-sample t- test was applied for comparisons between the two groups, i.e. 
Cav2.3
+/+ 
and Cav2.3
-/- 
mice. This procedure was utilized at a p-level of 0.05. All data 
were plotted as the mean ± SEM. Statistical analysis of delta wave amplitude post sleep 
deprivation was done using repeated measures ANOVA with time factor (within 
subjects factor, 12 intervals) and group factor (between-subjects factor, Cav2.3
+/+ 
and 
Cav2.3
-/-
).  
For a detailed analysis of the time factor, pairwise comparisons were done for the 
within-subjects factor. If necessary, Huynh- Feldt corrections were performed. 
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Results 
Electrocorticographic and electromyographic recordings in control and Cav2.3
-/- 
mice 
Control and Cav2.3
-/- 
mice were implanted using a two-channel radiofrequency 
transmitter allowing simultaneous electrocorticographic (SB1) and nuchal 
electromyographic recordings (Fig. 1; Fig. 2). As reported previously for a different 
Cav2.3
-/- 
mouse model (Weiergraber et al., 2006),
  
the Cav2.3 knock-out model used in 
this study (Wilson et al., 2000)
 
did not exhibit any type of spontaneous irregular EEG 
activity that might be indicative of seizure activity (Fig 1A,B; Fig. 2A,B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Depending on the stage of vigilance, electrocorticographic recording suggest 
predominance of different frequency bands, i.e. increased theta and delta frequency 
   
(SB1) (SB1) 
 (SB1) (SB1) 
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activity during SWS2 and less theta and delta, but increased beta activity during the 
active state. To demonstrate this phenomenon both the periodogram approach and 
power band analysis was carried out for the active state (Fig. 1E-H) and SWS2 state 
(Fig. 2E-H) for both genotypes. Initial power analysis suggests increased theta and delta 
activity in Cav2.3
-/- 
mice in the wake state (Fig. 1G,H; Fig. 2G,H). Note that EMG 
amplitude is dramatically reduced during SWS2 (Fig. 2C,D) compared to wake state 
(Fig. 1C,D) leading to the appearance of characteristics ECG- related R-spikes that 
represent the typical murine heart rate. Technically, ECG contamination is unavoidable 
in EMG recordings but of no relevance in epidural SB1 recordings (Weiergraber et al., 
2006; Weiergraber et al., 2007).  
Hypnogram 
Representative hypnograms (somnograms) are presented in Fig. 3 for a total period of 
48hrs. Comparison of Cav2.3
+/+ 
and Cav2.3
-/- 
hypnograms suggests an alteration in sleep 
architecture in Cav2.3
-/- 
with increased sleep duration and increased number of sleep 
stage episodes in knock-out mice (see section below). For precise sleep analysis the 
Neuroscore
® 
sleep module was used which allows for analysis of total duration, mean 
duration, total number and number of transitions of individual sleep stages. 
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Sleep architecture in control and Cav2.3
-/- 
mice 
We have analyzed the wake state for quiet, i.e. inactive wake and active wake. In 
general, the active wake state dramatically predominates in both genotypes. Further 
analysis of the quiet/active-wake state ratio defined as (1 –quiet wake /active wake)*100 
for both light and dark cycle revealed a significant increase of the quiet/active wake 
ratio in Cav2.3
-/- 
mice compared to controls during light cycle (0.989 ± 0.004 v. 0.950 ± 
0.011, p = 0.013). Cav2.3
-/- 
showed a clear tendency of reduced quiet wake duration 
compared to control mice with a significant reduction for the total observation period 
(50.60 ± 11.91 min v. 15.06 ± 4.45 min, p = 0.038) and the light cycle in specific (35.16 
± 7.26 min v. 7.78 ± 3.01 min, p = 0.008, Fig.4A).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The same trend was observed for the active  wake state during the total recording period 
(1825.72 ± 66.84 min v. 1424.64 ± 190.81 min, p = 0.051) with significant reduction in 
Cav2.3
-/- 
mice compared to controls during the dark cycle (1097.78 ± 24.25 min v. 
813.98 ± 77.71 min, p = 0.019, Fig. 4B). Whereas the quiet wake duration was not 
increased during the dark cycle compared to light cycle, the active wake duration was 
increased during dark episode compared to light episode in both genotypes (Cav2.3
+/+
, 
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727.94 ± 76.54 min v. 1097.78 ± 24.25 min; Cav2.3
-/-
, 610.66 ± 87.16 min v. 813.98 ± 
77.71 min, Fig. 4A,B). Analysis of total wake duration revealed significant reduction in 
Cav2.3
-/- 
mice versus controls during the dark cycle (826.23 ± 75.69 min v. 1158.93 ± 
46.50 min, p = 0.006) and the total observational period (1437.90 ± 164.56 min v. 
1876.38 ± 75.80 min, p = 0.042, Fig. 5A).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
For the paradoxical sleep, a trend for increased PS duration was observed during the 
dark cycle in Cav2.3
-/- 
mice versus controls (46.80 ± 11.29 min v. 20.27 ± 5.99 min, p = 
0.072, Fig. 5B). Interestingly, total SWS1 duration was increased in Cav2.3
-/- 
mice with 
significant SWS1 increase during the dark cycle (254.03 ± 29.88 min v. 87.23 ± 39.09 
min, p = 0.009, Fig. 5C). No difference could be detected regarding mean duration of 
individual sleep stages during 48 hrs recording (Fig. 5F) and for the light and dark 
cycles in specific (Fig. 6E-H).  
The total number of SWS1 and SWS2 episodes in 48 hrs recording was significantly 
increased in Cav2.3
-/- 
mice (SWS1, 1689.00 ± 137.13 v. 885.20 ± 183.82, p = 0.008; 
SWS2, 1573.60 ± 180.27 v. 834.20 ± 128.62, p = 0.010, Fig. 5E). This observation also 
held true for the light and dark cycle specific analysis of SWS1 and SWS2 episode 
numbers (Fig. 6C,D). In addition, a significant difference between both genotypes could 
be detected for the number of wake episodes during light cycle (282.80 ± 11.46 
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(Cav2.3
+/+
) v. 223.80 ± 11.18 (Cav2.3
-/-
), p = 0.006, Fig. 6A). In general, Cav2.3
+/+ 
mice 
exhibited a significant reduction of the number of all sleep stage episodes from light to 
jj 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
dark cycle, concomitant with an increase in mean wake duration from light to dark cycle 
(p = 0.053). This pattern severely differed from Cav2.3
-/- 
mice, in which the total number 
and mean duration of individual sleep stages remained largely unaffected by light-dark 
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transitions. Particularly, this observation points to a role of Cav2.3 R-type Ca
2+ 
channels 
in modulating sleep architecture via extrathalamocortical structures.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A detailed analysis of sleep transition states for the dark cycle revealed a significant 
increase in wake-SWS1 transitions and PS-SWS1 transitions in Cav2.3
-/-
compared to 
Cav2.3
+/+
mice(Wake-SWS1: 125.40 ± 18.59 v. 59.20 ± 20.82, p = 0.045; PS-SWS1: 
21.00 ± 4.59 v. 6.40 ± 1.86, p = 0.019, Fig. 7A,B).  
Moreover, a dramatic increase in SWS1-SWS2 and SWS2-SWS1 transitions was 
observed in Cav2.3
-/- 
mice (SWS1-SWS2, 563.00 ± 61.69 v. 176.40 ± 62.86, p = 0.002; 
SWS2-SWS1, 581.20 ± 62.40 v. 190.20 ± 69.01, p = 0.003, Fig. 7C,D) stressing the 
aforementioned alterations that became apparent in the hypnograms (Fig. 3; dark cycle).  
Though most changes were observed during the dark cycle as described above, 
significant alterations in SWS1-SWS2 and SWS2-SWS1 transitions were also observed 
 36 
 
during the light cycle and total 48 hrs recording period for Cav2.3
+/+ 
and Cav2.3
-/- 
mice 
(light cycle: SWS1- SWS2, 437.00 ± 69.09 v. 771.40 ± 76.56, p = 0.012; SWS2-SWS1, 
451.20 ± 72.96 v. 805.00 ± 82.55, p = 0.012; 48 hrs: SWS1-SWS2, 613.80 ± 131.56 v. 
1334.60 ± 136.92, p = 0.005, SWS2-SWS1, 641.40 ± 140.74 v. 1386.60 ± 144.07, p = 
0.006). These findings indicate that ablation of the Cav2.3 voltage-gated Ca
2+ 
channel 
results in complex alteration of sleep architecture. The individual sleep stages were 
systematically analyzed for changes in frequency band amplitude (Fig. 8).  
Interestingly, it turned out that in most cases a significant increase in amplitude for 
delta, theta and alpha frequency band could be detected for Cav2.3
-/- 
compared to 
controls (Fig. 8A-D).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This phenomenon was also observed in the light and dark periods (data not shown). 
This observation points to an increased degree of neuronal synchronisation in Cav2.3
-/- 
mice the physiological reason of which however remains to be elucidated. 
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Sleep deprivation in control and Cav2.3
-/- 
mice 
Following spontaneous sleep recordings we performed sleep deprivation experiments to 
identify potential SWS rebound mechanisms upon sleep recuperation. As this 
recuperation can occur immediately after sleep deprivation, with delay of some hours or 
be totally lacking depending on mouse strain and transgenic lines used, a total duration 
of 6 hrs (2:00 PM – 8:00 PM, light cycle) was used for analysis of sleep parameters. 
Although mean values for wake-, SWS1- and SWS2 duration (Supplemental Fig. 
2A,C,D) display the same tendency as observed in spontaneous 48 hrs sleep analysis 
(Fig. 5A,C,D), no significant difference was observed following sleep deprivation 
between both genotypes. The same holds true for analysis of transition states 
(Supplemenal Fig. 3).  
It should be noted that more rigorous sleep deprivation procedures were not applied as 
Cav2.3
-/-
mice were reported to exhibit increased levels of anxiety based on functional 
expression of Cav2.3 in the amygdala  (Lee et al., 2002). Given the complex reciprocal 
connections between the amygdala, the limbic system and brainstem structures involved 
in sleep regulation it seemed mandatory to use a gentle sleep deprivation approach to 
avoid any potential interference between anxiety and sleep behaviour. This potential 
bias in physiological, i.e. sleep-deprivation based SWS provocation was avoided by 
using a pharmacological approach in SWS induction (see below). In addition, we 
performed amplitude analysis of the δ frequency band of SWS1 and SWS2 episodes for 
the 6 hrs post sleep deprivation period in both genotypes. Changes in delta amplitude, 
∆Amplitude (mV), i.e. [EEG-Amplitude (post sleep depriation, 30 minutes intervals) – 
EEG-Amplitude (average baseline. 6 hrs)], was calculated and is displayed in Fig. 9. 
Statistical analysis revealed no significant difference between both genotypes. However, 
a group-specific (p = 0.088) and time-specific (p = 0.064) statistical trend was observed 
for SWS2 suggesting a higher delta amplitude following sleep deprivation in Cav2.3
+/+ 
mice compared to Cav2.3
-/- 
animals. For SWS1, a time-specific trend (p = 0.062), but 
not a group – specific one (p = 0.118) was observed. This finding might suggest that 
sleep deprivation provoked TC hyperoscillation is less in Cav2.3
-/- 
mice compared to 
controls which is in line with results reported by Zaman et al., 2011. 
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Urethane-induced artificial slow-wave sleep 
Following analysis of spontaneous sleep in control and Cav2.3
-/- 
mice we 
pharmacologically induced SWS using urethane (800 mg/kg ip.). 
Pharmacodynamically, urethane is a multi- target drug that serves i.a. as antagonist on 
NMDA receptors (Dalo and Hackman, 2013; Hara and Harris, 2002).
  
Simultaneous 
video-EEG- EMG recordings were performed 1 h prior to injection, up to 8 hrs post 
injection and analyzed using the Neuroscore
® 
sleep module. Individual sleep stages 
were quantified for one hour intervals. Statistical analysis revealed significant reduction 
of wake duration in Cav2.3
-/- 
mice compared to controls within the first hour post 
injection (352.00 ± 73.38 s v. 896.00 ± 150.59 s, p = 0.012) and significant increase of 
SWS1 duration in Cav2.3
-/-
mice during the second hour post urethane injection (1502.00 
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± 243.83 s v. 630.00 ± 148.09 s, p = 0.016, Fig. 10). These findings strongly support 
our results obtained from spontaneous sleep analysis. In addition, there is a tendency 
that wake duration in Cav2.3
+/+ 
mice is reduced following urethane injection (1
st – 2nd 
hr), whereas SWS1 duration remained constant. Interestingly, Cav2.3
-/- 
mice exhibited 
the opposite behaviour with constant wake duration but increase in SWS1.  
Thalamic expression pattern of Cav3 T-type Ca
2+ 
channels in controls and Cav2.3
-/- 
mice 
The expression levels of Cav3.1, Cav3.2, Cav3.3 T-type Ca
2+ 
channels in Cav2.3
+/- 
and 
Cav2.3
-/- 
mice were analysed and compared to those of Cav2.3
+/+ 
animals based on the 
procedure of Schmittgen and Livak (2008) (Supplemental Fig. 4; Tab. 1,2).
 
 
 
 
 
 
Fold changes of Cav3 T-type Ca
2+ 
channels  exhibit  no  significant  difference  between  
controls,  Cav2.3
+/-  
and  Cav2.3
-/-  
mice. These findings demonstrate that no thalamic 
alteration in Cav3.1-3.3 T-type Ca
2+ 
channel expression can account for altered sleep 
architecture in Cav2.3
-/- 
mice. 
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Discussion 
Our study demonstrates that Cav2.3 R-type Ca
2+ 
channels modulate fundamental sleep 
parameters in rodents in a light-dark cycle dependent manner. Major alterations were 
detected for quiet and active wake duration, SWS1 duration and total number of sleep 
episodes. Specifically, wake duration was decreased compared to controls with 
significant increase in SWS 1. Sleep analysis further pointed to an alteration of sleep 
architecture in Cav2.3
-/- 
mice due to aberration in sleep stage transitions. Interestingly, 
the most severe changes were observed during the dark cycle. Pharmacologically 
induced SWS following urethane administration clearly supported sleep scoring results 
from spontaneous 48 hrs sleep recordings. How can Cav2.3 VGCCs exert such a 
tremendous impact on sleep regulation? In a discussion on this issue one has to 
differentiate between thalamocortical and extrathalamocortical mechanisms. In a recent 
study on TC rhythmicity, Zaman et al., 2011
 
showed that there is a clear functional 
interdependence between Cav2.3 R-type Ca
2+
 channels, small-conductance Ca
2+
-
activated K
+ 
channels (SK) and T-type Ca
2+ 
channels that build-up functional 
microdomains in RTN neurons. Interestingly, Cav2.3 mediated Ca
2+ 
influx is capable of 
activating SK channels which results in re- and hyperpolarisation of the cell membrane 
causing repriming of T-type Ca
2+
-channels and activation of HCN channels. Thus, 
Cav2.3 R-type Ca
2+ 
channels seem to actively promote and sustain rebound burst firing 
in RTN neurons. Electrophysiological data from the RTN of Cav2.3
-/- 
mice clearly 
demonstrated an impairment of reticular thalamic bursting which was supposed to result 
in reduced SWD activity triggered by γ-hydroxybutyrate administration (Zaman et al., 
2011).
 
This functional scenario of Cav2.3 mediated SK2 activation has previously been 
described in the CA1 region as a mechanism to induce AHPs that might serve as a 
negative feedback in regulating synaptic activity and plasticity in dendritic spines 
(Bloodgood and Sabatini, 2007; Yasuda et al., 2003).
  
Based on the studies of Zaman et 
al., 2011
 
one might speculate that ablation of Cav2.3 R-type Ca
2+
 channels results in 
decreased slow wave sleep. It should be noted that anaesthetic sensitivities to propofol 
and halothane were shown to be decreased in Cav2.3
-/- 
mice probably due to different 
pharmacodynamics profiles compared to urethane (Takei et al., 2003).
 
Joksovic et al. 
(2009)
  
reported that presynaptic Cav2.3 R-type Ca
2+ 
channels support inhibitory 
gamma-aminobutyric acidA (GABAA) transmission in RTN neurons and are inhibited by 
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isoflurane. Recombinant and native T-type Ca
2+ 
channels are also potently inhibited by 
volantile anesthetics as well, including isoflurane (Joksovic et al., 2005; Todorovic et 
al., 2000).
  
Joksovic et al. (2009)
 
concluded that it is difficult to predict the 
consequences that an inhibition of Cav2.3 R-type Ca
2+ 
channels and IPSCs in the RTN 
might have on TC rhythmicity. We previously found that Cav2.3
-/- 
exhibited a decrease 
in the duration of suppression episodes in the EEG following isoflurane anesthesia 
(Joksovic et al., 2009)
 
which is in line with data from Zaman et al., 2011
 
assuming that 
Cav2.3 channels might play a role in deep sleep / deep anesthesia. However, urethane 
results from our present study do not support this view. This might be due to the 
different pharmacodynamic profile of urethane and the fact that urethane at a dose of 
800 mg/kg ip. induces light SWS but not deep anesthesia. Interestingly, our experiments 
show a non-significant trend of higher delta amplitude in Cav2.3
+/+ 
mice compared to 
Cav2.3
/- 
animals following sleep deprivation, suggesting a potential role of Cav2.3 in 
synchronisation of TC rhythmicity (Zaman et al., 2011) . In order to get an integrative 
view of Cav2.3 in sleep modulation, it is worthwhile to have a short glance at T-Type 
Ca
2+ 
channels in the TC system as well. Within the last decade, the functional 
involvement of T-Type Ca
2+ 
channels in rodent sleep architecture has been elaborated in 
detail, leading to a “Ca2+ channel model of thalamocortical rhythmity”. T-type Ca2+ 
channels are differentially distributed throughout the thalamus. Cav3.1 channels are 
expressed in thalamic relay cells whereas Cav3.2 and Cav3.3 channels are expressed in 
RTN neurons (Talley et al., 1999).
 
Gene ablation studies on Cav3.1
-/- 
mice showed that 
lack of Cav3.1 mediated Ca
2+ 
influx in thalamic relay cells results in lack of burst firing 
activity due to impaired low-threshold Ca
2+ 
spike activity (Lee et al., 2004).
 
However, 
region specific, i.e. cortical, not thalamic Cav3.1 deletion did not result in altered sleep 
(Anderson et al., 2005).
 
Generalized Cav3.1 ablation was capable of rescuing multiple 
Cav2.1 mouse mutants exhibiting SWD activity (Song et al., 2004; Zhang et al., 2002)
 
and SWDs were also shown to be accelerated upon thalamic Cav3.1 overexpression 
(Ernst and Noebels, 2009).
 
SWD are characteristic of absence like seizure activity 
which is supposed to be a pathophysiological aberration of SWS. Finally, these findings 
evolved into a well-described model of Cav3.1 T-type Ca
2+ 
channels in regulating 
thalamocortical rhythmicity. Based on this, it might be speculated that ablation of 
Cav3.2 and Cav3.3 in the RTN might result in a phenotype comparable to that of  
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Cav3.1
-/- 
mice (Cheong and Shin, 2013).
 
However, although effects of Cav3.3 ablation 
on sleep spindles have been described, we are still lacking detailed sleep analysis in 
Cav3.2 and Cav3.3 knock-out mice. The model might predict that ablation of Cav3.2 and 
Cav3.3 results in impaired SWS, however, it was recently reported from a patent 
application that pharmacological blockade of Cav3.2 channels can result in enhanced 
rather than impaired sleep, the reason of which remains to be determined. Moreover, 
transition rates and sleep architecture were altered (Lee and Shin, 2007). The latter 
findings strongly suggest that interpretation of sleep architecture in transgenic mice 
cannot be restricted to the thalamocortical network itself, or thalamic nuclei in specific. 
Like Cav3.2 and Cav3.3 channels, Cav2.3 channels are expressed in the RTN, but not 
thalamic relay neurons. In addition, Cav2.3 transcripts are present in cortical 
interneurons. Moreover, Cav2.3 channels are expressed in a number of 
extrathalamocortical structures,such as the mesopontine REM-NREM modulators (i.e 
the locus coeruleus, the dorsal raphe nuclei, the pedunculopontine and the laterodorsal 
tegmental nuclei), the diencephalic sleep onset controllers (i.e. hypothalamic nuclei 
including the ventrolateral/lateral preoptic region and the tuberomammillary basal 
forebrain), the cerebellum, the basal ganglia and the hippocampus (Weiergraber et al., 
2006; Weiergraber et al., 2007; Weiergraber et al., 2008; Zaman et al., 2011). These 
structures are known to project to the thalamocortical circuitry and substantially modify 
its activity via different neuromodulators, e.g. noradrenalin, histamine, serotonin (5-HT) 
and acetylcholine (Deransart et al., 1998; Khosravani and Zamponi, 2006; Manning et 
al., 2003; Pace-Schott and Hobson, 2002)
 
(Fig. 11). The suprachiasmatic nucleus, which 
is involved in the regulation of the circadian rhythm and also in sleep architecture, is 
also modulated by Cav2.3 channels (Merica and Fortune, 2011; Wurts and Edgar, 2000).
  
Both, suprachiasmatic AHP and plateau potentials were reported to be triggered by 
Cav2.3 channels (Cloues and Sather, 2003; Pierson et al., 2005).
 
This aspect is even 
more striking as sleep changes in Cav2.3
-/- 
mice seem to be dependent on light- dark 
cycles.  Special attention has to be paid to the role of the amygdala in sleep regulation. 
The central nucleus of the amygdala (ACE) has numerous neuroanatomical connections 
to the basal forebrain, hypothalamus and brainstem thus substantially modulating sleep 
architecture (Jha et al., 2005). Within the ACE individual neuronal cell entities, i.e. 
Wake-ON, REM-ON and NREM-ON neurons have been identified that are functionally 
distinct from each other and exhibit characteristic firing patterns (Jha et al., 2005).
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Interestingly, Cav2.3 plays a major role in the amygdala physiology. Lee et al (2002)
 
analyzed the molecular basis of R-type Ca
2+ 
channels in ACE neurons proving that 
Cav2.3 underlies R-type Ca
2+ 
currents in ACE neurons. In 40 % of ACE neurons an 
extremely high amount of Cav2.3 R-type based Ca
2+ 
current was observed. Importantly, 
deletion of Cav2.3 did not change expression of other VGCCs in ACE neurons. Thus, it 
is highly likely that R-type channel currents are substantially involved in the regulation 
of ACE neuronal excitability. Yet, it is not known what the functional consequences of 
Cav2.3 based R-type Ca
2+ 
currents in Wake-ON, REM-ON and NREM-ON ACE 
neurons are and how complex G-protein coupled neurotransmitter receptors are 
involved in modulating their activity. However, these findings illustrate that 
interpretation of sleep data in Cav2.3
-/- 
mice needs to consider more than RTN 
physiology and that altered extrathalamocortical input is likely to modulate 
thalamocortical oscillations in Cav2.3
-/- 
mice. It could further be speculated that 
compensatory alterations, particularly in T-type Ca
2+ 
channel expression might be 
related to altered sleep architecture in Cav2.3
-/- 
mice. Thus, we performed qPCR for 
Cav3.1-3.3 using thalamic RNA preparations from Cav2.3
+/+
, Cav2.3
+/- 
and Cav2.3
-/- 
mice. No significant up- or down-regulation of Cav3 T-type Ca
2+ 
channels could be 
detected. These findings further underline that sleep alterations in Cav2.3 deficient mice 
are directly related to Cav2.3 ablation itself. This of course does not exclude other 
potential changes in gene expression. Our studies demonstrate for the first time that 
Cav2.3 R-type Ca
2+ 
channels substantially modulate mammalian sleep architecture. 
Further studies are necessary to elucidate the pathophysiological implications of Cav2.3 
Ca
2+ 
channels in the thalamocortical system and extrathalamocortical modulators and 
their potential role in sleep disorders.  
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Abstract 
Alzheimer’s disease (AD) has been associated with increased phosphorylation of the 
translation initiation factor elF2α at serine 51. Increased phosphorylation of elF2α 
causes global repression of protein synthesis, while stimulating the expression of 
specific transcripts, such as those encoding activating transcription factor 4 (ATF4) and 
ß-site APP cleaving enzyme 1 (BACE1). Increased expression of ATF4 may inhibit 
synaptic plasticity, learning and memory, whereas elevated BACE1 levels may promote 
amyloid-ß (Aß) generation and therefore favor amyloid accumulation in the brain. To 
analyze if increased levels of phosphorylated elF2α indeed promote learning and 
memory impairments and/or amyloidogenesis in a mouse model of Alzheimer’s disease, 
we crossed 5XFAD transgenic mice with an elF2αS51A knock-in line that expresses the 
non-phosphorylatable elF2α variant elF2αS51A. Behavioural assessment of the resulting 
mice revealed motor and cognitive deficits in 5XFAD mice that were, for the most part, 
not restored by the elF2αS51A allele. The elF2αS51A allele, however, appeared to have a 
rescue effect on hyperactivity in the 5XFAD model, the mechanistic underpinnings of 
which deserve further attention in future studies. Telemetric intracranial EEG 
recordings revealed seizures in both groups with the 5XFAD transgene, indicating that 
the elF2αS51A allele had no measureable effect on epileptic activity in this model. 
Transcriptome analyses showed clear transcriptional alterations in 5XFAD 
hippocampus that were not corrected by the elF2αS51A allele. In contrast to prior studies, 
our immunoblot analyses did not reveal increased levels of p-elF2α and BACE1 in the 
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hippocampus of 5XFAD mice, suggesting that elevated p-elF2α levels are not a 
universal feature of Alzheimer’s disease models.  
Collectively, our data indicate that 5XFAD-related pathologies do not necessarily 
require hyperphosphorylation of elF2α to emerge; they also show that heterozygosity 
for the non-phosphorylatable elF2αS51A allele has limited effects on 5XFAD-related 
disease manifestations. 
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Introduction 
Alzheimer’s disease is associated with progressive cognitive and neurological 
impairments. Synaptic dysfunction downstream of toxic amyloid species is thought to 
play a major role in altered brain function and cognitive impairments in Alzheimer’s 
disease (Palop and Mucke, 2010). A growing body of literature suggests that 
translational regulatory mechanisms are disrupted in Alzheimer’s disease (Ding et al., 
2005; Gamliel et al., 2002; Langstrom et al., 1989). More specifically, Alzheimer’s 
disease has been associated with elevated phosphorylation levels of the eukaryotic 
translation initiation factor 2 (elF2α) (Chang et al., 2002; Choi et al., 2007; Kim et al., 
2007; O'Connor et al., 2008). elF2α is phosphorylated in the context of cellular stress 
responses, such as the unfolded protein response; increased eIF2 phosphorylation then 
leads to a general inhibition of protein synthesis (Harding et al., 1999). In addition, 
elevated eIF2 phosphorylation favors the translational expression of certain mRNAs, 
such as the ones encoding for the transcription factor ATF4 (Blais et al., 2004). De novo 
protein synthesis is well known to play import roles in the establishment of long-lasting 
synaptic plasticity and the formation of long-term memory (Costa-Mattioli et al., 2009; 
Klann and Dever, 2004). Hyperphosphorylation of elF2α may interfere with protein 
synthesis-dependent forms of plasticity and memory formation by inhibiting de novo 
protein synthesis (Costa-Mattioli et al., 2005). Additionally, eIF2 
hyperphosphorylation may perturb synaptic plasticity and memory formation by 
suppressing CREB-dependent gene expression via upregulation of ATF4 (Costa-
Mattioli et al., 2005). These considerations suggest that p-eIF2-mediated translational 
and transcriptional effects may contribute to altered plasticity and cognitive dysfunction 
in Alzheimer’s disease. Indeed, it was reported recently that the genetic removal of 
either of two different eIF2 kinases (Perk and Gcn2, respectively) restores plasticity 
and memory impairments in an APP/PS1 mouse model of Alzheimer’s disease (Ma et 
al., 2013). We, here, set out to explore the role of elF2α phosphorylation in Alzheimer’s 
pathogenesis by crossing the 5XFAD mouse model (Oakley et al., 2006) with an 
elF2αS51A knock-in line (Scheuner et al., 2001), in which elF2α cannot be 
phosphorylated on the mutant allele due to substitution of serine at residue 51 by 
alanine. We analyzed the effects of the elF2αS51A allele on cognitive impairments, as 
well as general disease progression seen in 5XFAD animals. 
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Material and Methods 
Animals 
5XFAD mice (genetic background: B6/SJL) overexpress mutant forms of human APP 
(the Swedish mutation: K670N, M671L; the Florida mutation: I716V; the London 
mutation: V717I) and mutant PSEN1 (M146L, L286V) (Oakley et al., 2006). 
elF2α+/S51A mice (genetic background: C57BL/6J) were generated as previously 
described (Scheuner et al., 2001). 5XFAD mice were crossed with elF2α+/S51A mice, 
yielding animals of four different genotypes: wild-type, 5XFAD, 5XFAD;elF2α+/S51A, 
elF2α+/S51A. Our studies were performed using heterozygous elF2αS51A mutant mice 
because homozygous elF2αS51A mutants die shortly after birth (Scheuner et al., 2001) 
and are therefore not suitable to address the aims of the present paper. One cohort of 
animals was generated for behavioural and neurological assessments. Tests were 
conducted in the following order / at the following age of the animals: open field (8 
months, 11 months), wire hang test (10-11 months), tail suspension test (10-11 months), 
Morris water maze (12 months), contextual fear conditioning (13-14 months). Ages of 
animals used for electrophysiological, biochemical and gene expression analyses are 
provided in the respective sections below (see below). The present study was approved 
by ‘Landesamt für Natur, Umwelt und Verbraucherschutz Nordrhein-Westfalen’ 
(Recklinghausen, Germany). 
 
Tail suspension test 
Assessment of pathological hindlimb clasping was performed using the tail suspension 
test. Hindlimb movements in the test were assigned to one of the four following 
categories: 1 = normal hindlimb movements, 2 = intermittent clasping of one hindlimb, 
3 = intermittent clasping of both hindlimbs, 4 = enduring clasping of both hindlimbs. 
Statistical analysis was performed by ordered logistic regression with the factors of 
“5XFAD genotype” (5XFAD transgenes present vs. absent) and “elF2α genotype” 
(elF2α+/S51A vs. elF2α+/+).  
 
Wire hang test 
Mice were placed on a wire cage lid, which was turned upside down and positioned 
about 25 cm above an empty cage. Latency to fall was recorded with a maximum 
duration of 10 min. Mice received one trial per day over a period of 3 days (latencies 
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were averaged across these trials). Statistical analysis was performed using two-way 
ANOVA with the between-subject factors “5XFAD genotype” (5XFAD transgenes 
present vs. absent) and “elF2α genotype” (elF2α+/S51A vs. elF2α+/+). 
 
Open field 
To assess motor activity in a novel environment, mice were placed in an open field 
(27.5 cm x 27.5 cm x 20 cm) for 20 min on each of 3 consecutive days. The distance 
travelled was recorded using the EthoVision XT video tracking system (Noldus, 
Wageningen, the Netherlands) and an average across all 3 sessions was calculated for 
each animal. Statistical analysis was performed using two-way ANOVA with the 
between-subject factors “5XFAD genotype” (5XFAD transgenes present vs. absent) and 
“elF2α genotype” (elF2α+/S51A vs. elF2α+/+). 
 
Morris water maze 
Mice were trained on a hidden version of the Morris water maze (Ø 135 cm). In this 
task animals learned to find an escape platform (Ø 10 cm) hidden underneath the water 
surface in a constant location of the pool. Mice received 6 trainings trials per day for 7 
consecutive days. Training trials were completed when the animal had reached the 
escape platform or when 60 s were elapsed, whichever came first. During training trials, 
animals were started from randomly alternating starting positions. If animals did not 
manage to get on the escape platform within 60 s, they were gently guided to the escape 
platform. There was a 15 s post-trial period on the escape platform. To test how well the 
animals had learned the position of the escape platform, we gave a probe trial at the end 
of training day 7. During the probe trial the platform was removed from the pool and the 
swim pattern was analyzed (with respect to quadrant occupancy and target crossings). 
After completion of the 7 days of hidden training, we gave one day of cued training (6 
trials), during which the platform position was indicated by a visible cue. Swim patterns 
of mice were recorded using the EthoVision XT video tracking system (Noldus, 
Wageningen, the Netherlands). Time spent in quadrants and target crossings were 
analyzed using the built-in features of the software. Further analyses were done based 
on the raw time-tagged xy-coordinates using Matlab (The Mathworks). Search 
strategies were classified according to parameters described in our previous study 
(Garthe et al., 2009), originally based on (Balschun et al., 2003). Search strategies were 
defined by no more than two quantitative parameters that were chosen to reflect the 
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unique abstract properties of a given strategy and that were not dependent on the 
specific pool dimensions used. Statistical analysis of the groups was done by three-way 
repeated-measures ANOVA with the between-subject factors “5XFAD genotype” 
(5XFAD transgenes present vs. absent) and “elF2α genotype” (elF2α+/S51A vs. elF2α+/+) 
and one of the following within-subjects factors: training trials (for the analysis of the 
escape latency curves), quadrants (for the analysis of probe trial data, i.e. target 
crossings and quadrant occupancy, respectively).  
 
Contextual fear conditioning 
Mice were placed in a conditioning chamber (Med Associates, St. Albans, Vermont, 
USA) for 3 min and received foot shocks (0.75 mA, 2 s) after minutes 1 and 2. One day 
later, for testing, mice were again placed in the conditioning chamber for a period of 3 
min. Freezing behaviour, as well as activity levels during the baseline (i.e., first minute 
on the training day) and the test were recorded and analysed using Video Fear 
Conditioning software (Med Associates, St. Albans, Vermont, USA). Due to differences 
in baseline activity levels between groups (data not shown), we do not report freezing 
scores, but report activity suppression ratios instead, which were calculated as follows: 
activity test / (activity baseline + activity test). Statistical comparison of the groups was 
performed by two-way ANOVA with the between-subject factors “5XFAD genotype” 
(5XFAD transgenes present vs. absent) and “elF2α genotype” (elF2α+/S51A vs. elF2α+/+). 
 
Radiotelemetric EEG recordings 
Mice (>10 months of age) were anesthetized by intraperitoneal injection containing 
ketamine (KetanestR, Parke-Davis/Pfizer, Germany) / xylazine (RompunR 2%, Bayer 
Vital, Germany) at 100/10mg/kg. For measuring of the electroencephalogram (EEG), 
TL11M2-F20-EET 2-channel transmitters (technical specification: 3.9 g, 1.9 cc; Data 
Science International (DSI), USA) were implanted into a subcutaneous pouch on the 
back of the animals. The first channel was used to target the primary motor cortex 
region (M1). A differential epidural electrode was placed at the following stereotaxic 
coordinates: (M1)-lead bregma +1 mm, lateral of bregma 1.5 mm (left hemisphere). For 
deep brain recordings targeting the hippocampal CA1 region, the differential electrode 
of channel 2 was positioned as follows: (CA1)-lead, bregma -2 mm, lateral of bregma 
1.5 mm (right hemisphere), dorsoventral (depth) 1.5 mm. For both channels, epidural 
reference electrodes were placed at: bregma -6 mm, lateral of bregma 1 mm (left 
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hemisphere) and bregma -6 mm, lateral of bregma 1 mm (right hemisphere). Electrodes 
were fixed at the neurocranium using glass ionomer cement (Kent Express, UK), and 
the scalp was closed using over and over sutures (Ethilon, 6-0). A detailed description 
of the implantation procedure is provided elsewhere (Weiergraber et al., 2005). For 
post-operative pain management carprofen (5 mg/kg; Rimadyl, Pfizer, Germany) was 
administered subcutaneously to the animals. Following a 10-day recovery period, 
simultaneous video-EEG recordings from the motor cortex (M1) and the hippocampal 
CA1 region were performed for 48 h using Dataquest ART 4.2 software (DSI) at a 
sampling rate of 500 Hz with no a priori filter cut-off. For further analyses, data were 
processed using Neuroscore
®
 2.1 (DSI). Seizure analyses and calculations were 
performed using Neuroscore Spike Train Detector, i.e. a seizure detection module. 
Seizure protocols contained total number of episodes and spikes, spike frequency, total 
spike train duration, shortest and longest spike train duration.  
 
Histology and immunostaining 
Mice (13 months old) were anaesthetized by intraperitoneal injection of ketamine (100 
mg/kg) and xylazine (7 mg/kg). For perfusion, the bloodstream was rinsed with sterile 
0.9% sodium chloride and organs were fixed using 4% paraformaldehyde (PFA) in 
phosphate buffered saline (PBS). Brains were dissected and post-fixed in 4% PFA in 
PBS overnight at 4°C and dehydrated in 30% sucrose in PBS at 4°C. Coronal brain 
sections of 40 µm thickness were cut using a sliding microtome (Leica, Wetzlar, 
Germany) and were stored in cryoprotectant buffer (0.05 M phosphate buffer, 25% 
glycerol and 25% ethylene glycol) at -20°C. Brain sections spaced 240 µm apart were 
transferred into Tris-buffered saline (TBS), washed twice for 5 min each and incubated 
in 0.6% H2O2 in TBS for 30 min. Sections were then washed three times in TBS for 5 
min. For blocking, sections were incubated for 30 min in TBS-plus (TBS, 0.1% Triton 
X-100 and 3% donkey serum). Next, sections were incubated with primary antibody 
(rabbit anti-choline acetyltransferase (ChAT), 1:100, Millipore, Darmstadt, Germany) in 
TBS-plus for 48 h at 4°C, washed twice in TBS for 5 min and blocked in TBS-plus for 
45 min. This was followed by a 1-hour incubation step (at room temperature) in TBS-
plus containing biotin-conjugated secondary antibody (donkey anti-rabbit, 1:500, 
Jackson ImmunoResearch Laboratories, West Grove, Pennsylvania, USA). Sections 
were then washed three times in TBS for 5 min and incubated in 3,3'-Diaminobenzidine 
(DAB) for 2 min using the DAB Substrate Kit (Roche, Mannheim, Germany). To stop 
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the peroxidase reaction, sections were washed in tap water and TBS. Next, sections 
were mounted on glass slides, dehydrated in an ascending series of alcohol (twice 70%, 
once 96%, twice 100% Ethanol), cleared in xylene and covered with a coverslip. 
Stereological analysis of brain sections was performed using a bright field microscope 
Eclipse 90i (Nikon, Düsseldorf, Germany). Immunoreactive neurons within the medial 
septum (MS) and vertical limb of the diagonal band of Broca (VDB) were quantified 
using the software Stereo Investigator (MBF Bioscience, Magdeburg, Germany). 
Statistical analysis was performed via two-way ANOVA with the between-subject 
factors “5XFAD genotype” (5XFAD transgenes present vs. absent) and “elF2α 
genotype” (elF2α+/S51A vs. elF2α+/+). 
 
Immunoblot analysis 
Hippocampal samples were taken from 14- to 15-month-old mice after cervical 
dislocation and snap-frozen in liquid nitrogen. Each sample was homogenized in 250 µl 
lysis buffer containing RIPA buffer, Phospho-Stop (Roche, Mannheim, Germany), 
Protease-Inhibitor (Roche, Mannheim, Germany), 50 mM sodium fluoride and 5 mM 
sodium orthovanadate and incubated on a rotator for 30 min at 4°C. Samples were 
centrifuged at 14000 rpm for 15 min at 4°C. Protein concentration was determined 
using the Pierce BCA protein assay kit (Thermo Fisher Scientific, Bonn, Germany). If 
not stated otherwise, 15 µg protein was loaded on 10% tris glycine gels (APP, BACE1, 
ChAT, elF2α) or 16% tris tricine gels (CTF) for PAGE. Proteins were transferred onto a 
polyvinylidene difluoride (PVDF) membrane and incubated in TBS with 10% Western 
Blocking Reagent (Roche, Mannheim, Germany) for 1 h. Incubation of PVDF 
membrane in primary antibody (rabbit anti-elF2α, 1:2000, Cell Signaling, Danvers, 
Massachusetts, USA; rabbit anti-p-elF2α, 1:2000, Cell Signaling, Danvers, 
Massachusetts, USA; rabbit anti-APP, 1:1000, Cell Signaling, Danvers, Massachusetts, 
USA; rabbit anti-CTF, 1:1000, Sigma-Aldrich, Taufkirchen, Germany; rabbit anti-
BACE1, 1:1000, Abcam, Cambridge, UK; goat anti-ChAT, 1:1000, Millipore, 
Darmstadt, Germany; mouse anti Beta Amyloid, clone 6E10, 1:1000, Covance, 
Princeton, NJ, USA; mouse anti-α-tubulin, 1:20000, Abcam, Cambridge, UK; mouse 
anti-β-actin, 1:5000, MP Biomedicals, Solon, Ohio, USA) in TBS with 5% Western 
Blocking Reagent was carried out overnight at 4°C. After multiple washing steps in 
TBS with 0.1% Tween-20, membranes were incubated in horseradish peroxidase-
conjugated secondary antibody (donkey anti-rabbit IgG, 1:1000, Jackson 
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ImmunoResearch Laboratories, West Grove, Pennsylvania, USA; donkey anti-mouse 
IgG, 1:1000, Jackson ImmunoResearch Laboratories, West Grove, Pennsylvania, USA; 
donkey anti-goat IgG, 1:10000, Jackson ImmunoResearch Laboratories, West Grove, 
Pennsylvania, USA) in TBS with 5% Western Blocking Reagent (for 1 h at room 
temperature or overnight at 4°C). Next, membranes were washed several times in TBS 
with 0.1% Tween-20. Immunosignals were detected using enhanced chemiluminescence 
(Amersham ECL Western Blotting Detection Reagents, GE Healthcare, Munich, 
Germany or SuperSignal West Femto Maximum Sensitivity Substrate, Thermo Fisher 
Scientific, Bonn, Germany) and were quantified using a Chemidoc XRS imager (Bio-
Rad, Munich, Germany). Densitometric analysis was performed using Image Lab 
software (Bio-Rad, Munich, Germany). Proteins were normalized to α-tubulin or ß-
actin, phosphorylated proteins were normalized to their respective total proteins. elF2α 
and p-elF2α were detected on different blots together with the respective loading 
controls. Statistical analysis was accomplished by t-test or two-way ANOVA with the 
between-subject factors “5XFAD genotype” (5XFAD transgenes present vs. absent) and 
“elF2α genotype” (elF2α+/S51A vs. elF2α+/+), as appropriate.  
 
Amyloid beta enzyme-linked immunosorbent assays 
Hippocampal homogenates in RIPA buffer (as described above) were used for 
quantitative analysis of the two abundant species of Amyloid ß (Aß), Aß40 and Aß42, 
using ELISA kits (Life Technologies, Carlsbad, CA, USA) according to manufacturer’s 
instructions. Amounts of Aß peptides were subsequently normalized to protein 
concentration of each respective sample.  
 
RNA extraction and Affymetrix microarray procedures 
Microarray experiments were carried out using Mouse Exon ST arrays (Affymetrix). 
Total RNA (250 ng) with integrity numbers about 10 of 14- to 15-month-old mice was 
used as starting material. Arrays were washed and stained according to the 
manufacturer’s recommendations. Labeled and purified cDNA was fragmented (5.5 µg) 
and subsequently hybridized to the arrays before scanning in a GeneChip 3000 7G 
scanner (Affymetrix). Normalization to the median of all samples, background 
correction as well as statistical analysis was performed with GeneSpringGX software 
(Agilent technologies). An implemented GC-RMA algorithm was applied on all chips 
to summarize probe level information. Microarray data were analyzed using unpaired t-
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tests. An uncorrected significance level p < 0.05 was adopted in all instances. 
Differentially regulated transcripts with a fold change (FC) greater than 1.6 were then 
subjected to hierarchical clustering analysis in order to visualize gene expression 
changes across groups. Array data are available in the GEO database under GSE50521. 
DAVID (Huang et al., 2009) was used to carry out gene ontology enrichment analyses 
in the gene set differentially expressed between 5XFAD and wild-type controls. 
 
Statistical analyses 
Statistical analyses were performed as described above. P < 0.05 was considered 
statistically significant. 
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Results 
In order to test if increased elF2α phosphorylation contributes to cognitive dysfunction 
and disease progression in 5XFAD mice, we crossed these mice with an elF2αS51A 
knock-in line (Scheuner et al., 2001), in which elF2α cannot be phosphorylated on one 
allele due to substitution of serine at residue 51 by alanine. We performed Western blot 
analyses to measure the abundance of p- elF2α (i.e., eIF2 phosphorylated at serine 51), 
total eIF2, BACE1, APP and APP cleavage products in lysates prepared from 
hippocampal tissue of 5XFAD, 5XFAD;elF2α+/S51A, elF2α+/S51A animals as well as 
wild-type controls. Unexpectedly, our analyses showed no significant effect of the 
5XFAD transgenes on p-elF2α levels (Figure 1A; two-way ANOVA with between-
subjects factors 5XFAD genotype and elF2α genotype, effect of 5XFAD genotype, p = 
0.15). Consistent with previously published work (O'Connor et al., 2008), the 5XFAD 
transgenes affected total elF2α levels with slightly increased elF2α abundance in 
animals bearing the 5XFAD transgenes (Figure 1A; two-way ANOVA with between-
subjects factors 5XFAD genotype and elF2α genotype, effect of 5XFAD genotype, p = 
0.01). The elF2α phosphorylation status did not differ significantly between 
heterozygous carriers of the elF2αS51A mutation and animals carrying two wild-type 
elF2α alleles (Figure 1A; two-way ANOVA with between-subjects factors 5XFAD 
genotype and elF2α genotype, effect of elF2α genotype, p = 0.62), which is in line with 
published data (Scheuner et al., 2001), and indicates that the heterozygous elF2αS51A 
mutation is not sufficient, at least under basal conditions, to reduce p-elF2α abundance 
(unlike the elF2αS51A mutation in the homozygous state that leads to the expected 
abolishment of elF2α phosphorylation (Scheuner et al., 2001). These biochemical 
findings suggest that an excessive elF2α phosporylation is not a universal feature of 
Alzheimer’s disease mouse models, such as 5XFAD mice, and they also indicate that 
the heterozygous elF2αS51A mutation is not sufficient to suppress hippocampal elF2α 
phosphorylation, at least under basal conditions. Further Western blot analyses showed 
no clear effects of the elF2αS51A mutation on the abundance of total APP (Figure 1B; 
two-way ANOVA with between-subjects factors 5XFAD genotype and elF2α genotype, 
effect of elF2α genotype, p = 0.31), human APP (Figure 1B; t-test, 5XFAD vs. 
5XFAD;elF2α+/S51A, p = 0.97), and APP cleavage products (Figure 1C; α-CTF, t-test, 
5XFAD vs. 5XFAD;elF2α+/S51A, p = 0.66; ß-CTF, t-test, 5XFAD vs. 
5XFAD;elF2α+/S51A, p = 0.39). ELISA analyses showed no group differences regarding 
 60 
 
hippocampal Aß40 and Aß42 concentrations (Figure 1D; Aβ40, t-test, 5XFAD vs. 
5XFAD; elF2α +/S51A, p = 0.90; Aß42, t-test, 5XFAD vs. 5XFAD;elF2α+/S51A, p = 0.30). 
Western blot analyses of BACE1 abundance also showed no discernable difference 
between groups (Figure 1E; two-way ANOVA with between-subjects factors 5XFAD 
genotype and elF2α genotype, effect of 5XFAD genotype, p = 0.77; effect of elF2α 
genotype, p = 0.81; 5XFAD x elF2α interaction, p = 0.75).In line with these 
biochemistry results, our behavioural, electrophysiological and gene expression 
analyses revealed limited effects of the elF2αS51A allele on disease phenotypes present in 
5XFAD mice, as outlined below. In brief, the elF2αS51A allele did not appear to 
ameliorate pathological hindlimb clasping in 5XFAD mice (Figure 2A; ordered logistic 
regression, effect of 5XFAD trangenes, p < 0.0001; effect of elF2α genotype p = 0.941; 
5XFAD genotype x elF2α genotype interaction, p = 0.081), nor was there any apparent 
effect on motor impairments as measured in the wire hang test (Figure 2B; two-way 
ANOVA with between-subjects factors 5XFAD genotype and elF2α genotype, effect of 
5XFAD genotype, p < 0.0001; effect of elF2α genotype, p = 0.56; 5XFAD x elF2α 
interaction, p = 0.87). We analyzed learning and memory using a context fear 
conditioning paradigm (Figure 2C) and the Morris water maze (Figure 2D-G). In 
context fear conditioning, 5XFAD mice showed higher activity suppression scores upon 
testing, indicative of associative learning impairments in these animals (Figure 2C; 
two-way ANOVA with between-subjects factors 5XFAD genotype and elF2α genotype, 
effect of 5XFAD genotype, p = 0.0003), that were not influenced by the elF2αS51A allele 
in any obvious way (Figure 2C; two-way ANOVA with between-subjects factors 
5XFAD genotype and elF2α genotype, effect of elF2α genotype, p = 0.94; 5XFAD x 
elF2α interaction, p = 0.87). In the Morris water maze, 5XFAD animals showed 
substantially higher escape latencies during training trials than controls (Figure 2D; 
three-way repeated-measures ANOVA with 5XFAD genotype and elF2α genotype as 
between-subjects factors and training trial as within-subjects factor, effect of 5XFAD 
transgenes, p < 0.0001; effect of elF2α genotype, p = 0.76; 5XFAD x elF2α interaction, 
p = 0.67), as well as a reduced number of target crossings during the probe trial given 
after completion of training (Figure 2F; three-way repeated-measures ANOVA with 
5XFAD genotype and elF2α genotype as between-subjects factors and quadrant as 
within-subjects factor, 5XFAD genotype x quadrant interaction, p = 0.03; elF2α 
genotype x quadrant interaction: p = 0.89; elF2α genotype x 5XFAD genotype x 
quadrant interaction: p = 0.58). An extended strategy analysis, in the context of which 
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behaviours during the training trials were classified into increasingly hippocampus-
dependent (directed search, focal search, direct swimming), as well as primarily 
hippocampus-independent (chaining, scanning, random search, thigmotaxis) search 
categories, revealed an excessive use of less hippocampus-dependent strategies in 
animals with the 5XFAD transgenes (Figure 2G). The elF2αS51A allele had no obvious 
modulatory effect on any of these 5XFAD water maze phenotypes (Figure 2D-G).   
Our behavioural analyses did, however, reveal one neurobehavioural 5XFAD phenotype 
that appeared to be restored by the elF2αS51A allele (Figure 2H,I). 5XFAD animals 
showed pronounced motor hyperactivity in an open field assay (two-way ANOVA with 
5XFAD genotype and elF2α genotype as between-subjects factors, effect of 5XFAD 
genotype, p = 0.02 and 0.0003, respectively). 5XFAD-related hyperactivity appeared to 
be reduced in animals carrying the elF2αS51A allele (two-way ANOVA with 5XFAD 
genotype and elF2α genotype as between-subjects factors, 5XFAD x elF2α genotype, p 
= 0.06 for panel H and p = 0.07 for panel I). The neurobiolology underlying this 
possible elF2αS51A-mediated rescue of 5XFAD-related hyperactivity remains to be 
elucidated. Here, we considered one possibility and that is that the elF2αS51A allele 
modifies the degeneration of the cholinergic system in 5XFAD animals, which may 
contribute to hyperactive behaviours in AD mouse models (Bellucci et al., 2006; 
Boncristiano et al., 2002; Christensen et al., 2010; Devi and Ohno, 2010; Perez et al., 
2007). Initial stereological cell countings showed neither a significant effect of the 
5XFAD transgenes (two-way ANOVA with 5XFAD genotype and elF2α genotype as 
between-subjects factors, effect of 5XFAD genotype, p = 0.74) nor an effect of the 
elF2αS51A allele (two-way ANOVA with 5XFAD genotype and elF2α genotype as 
between-subjects factors, effect of elF2α genotype, p = 0.32) on the number of ChAT-
positive neurons in the basal forebrain (Supplementary Figure 1). Western blot 
analyses of ChAT abundance in the hippocampus, one of the target areas that basal 
forebrain cholinergic neurons project into, however, revealed lower ChAT levels in 
animals carrying the 5XFAD transgenes (Supplementary Figure 1; two-way ANOVA 
with 5XFAD genotype and elF2α genotype as between-subjects factors, effect of 
5XFAD genotype, p = 0.002). The elF2αS51A allele had no apparent effect on 
hippocampal ChAT expression (two-way ANOVA with 5XFAD genotype and elF2α 
genotype as between-subjects factors, effect of elF2α genotype, p = 0.49) and also 
showed no significant interaction with the 5XFAD genotype (two-way ANOVA with 
5XFAD genotype and elF2α genotype as between-subjects factors, 5XFAD x elF2α 
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genotype interaction, p = 0.78), indicating that the elF2αS51A allele did not protect 
against the hippocampal ChAT loss in 5XFAD mice. Network hyperexcitability and 
seizures are important features of animal models of Alzheimer’s disease (Palop and 
Mucke, 2009; Verret et al., 2012). We performed electrocorticographic (M1) and deep 
intrahippocampal CA1 EEG recordings in 5XFAD animals crossed into the elF2αS51A 
background (Figure 3). Qualitative and quantitative seizure analysis using Neuroscore 
Seizure Module (DSI) revealed that animals of all genotypes with the exception of wild-
type animals exhibited seizure activity in the M1 recording, although ictal discharges 
were not seen in the deep, intrahippocampal CA1 recording (in none of the groups; not 
shown). Video analysis revealed that none of the cortical seizures was associated with 
motoric exacerbation. Thus, we observed predominantly non-convulsive seizure activity 
in 5XFAD mice. elF2α+/S51A mice showed non-convulsive seizure activity as well and 
introduction of the elF2αS51A mutation in 5XFAD mice did not appear to modify the 
epileptic phenotype in any apparent way. Alzheimer’s disease is associated with 
considerable transcriptional alterations in key brain areas (Blalock et al., 2004; 
Colangelo et al., 2002; Liang et al., 2008; Loring et al., 2001). Microarray analyses 
performed on hippocampal tissue of 5XFAD animals crossed into the elF2αS51A 
background revealed a number of 5XFAD-related transcriptional alterations: Statistical 
analysis applying an uncorrected significance level of p < 0.05, revealed 1421 
transcripts differentially regulated between 5XFAD mice and wild-type controls. Of 
these transcripts, we highlight a set of 139 genes with a fold change greater than ±1.6 
(Supplementary Figure 2). Gene ontology analysis of these 139 candidate genes 
showed a substantial enrichment of immune-response related genes in this gene set 
(Supplementary Table 1), which is in agreement with considerable inflammatory and 
immunological alterations observed in the context of late-stage cerebral amyloidosis. 
Comparison of the expression patterns of 5XFAD and 5XFAD;elF2α+/S51A animals 
revealed a striking 98.56% congruence. Only 2 out of the 139 selected candidate genes 
differed in their expression pattern between 5XFAD and 5XFAD;elF2α+/S51A (H2-Aa 
(histocompatibility 2, class II antigen A) and Cd74 (HLA class II histocompatibility 
antigen gamma), indicating that the elF2αS51A mutation only very slightly modified the 
hippocampal transcriptional changes induced by the 5XFAD transgenes.  
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Discussion 
In this study, we assessed the effects of a non-phosphorylatable elF2α allele (elF2αS51A) 
on disease progression in the 5XFAD mouse model of familial AD. While profound 
pathology was evident in 5XFAD mice, these abnormalities remained mostly 
unmodified by the heterozygous elF2αS51A mutation. This was the case for a wide range 
of molecular (APP expression and processing; gene expression), electrophysiological 
(EEG) and neurobehavioural (motor impairments; learning and memory impairments) 
features of the model. In contrast to previously published elevated p-elF2α levels in the 
whole brain of 5XFAD mice (Devi and Ohno, 2010; O'Connor et al., 2008), we did not 
observe changes in hippocampal p-elF2α levels in 5XFAD and 5XFAD;elF2α+/S51A 
mice. Also, hippocampal BACE1 expression levels did not differ between the groups of 
mice used in the present study. We currently do not know the factors that might account 
for these discrepant findings. Possibilities that need to be formally addressed in future 
studies include differences in genetic background, on which the 5XFAD mutations were 
kept, as well as differences in the brain areas examined (whole brain in previous reports 
(Devi and Ohno, 2010; O'Connor et al., 2008) versus hippocampus in the present study). 
Ma et al. recently reported that conditional homozygous deletion of either of two 
different elF2α kinases (Perk, Gcn2) in forebrain neurons improved spatial memory 
impairments in the APPswe/PSEN1dE9 mouse model of Alzheimer’s disease (Ma et al., 
2013). Deletion of either Perk or Gcn2 led to reduced p-elF2α levels in this model (Ma 
et al., 2013), suggesting that these genetic manipulations were more effective in 
suppressing elF2α phosphorylation than the heterozygous elF2αS51A mutation used in 
the present study. Accordingly, limited effects on neurological impairments observed in 
our study could be related to a less effective suppression of p-eIF2 levels by the 
heterozygous elF2αS51A mutation. Homozygous elF2αS51A mutants could not be 
examined because of early postnatal lethality associated with this genotype (Scheuner et 
al., 2001). Moreover, amyloid pathology progresses at a faster pace in 5XFAD animals 
(used in the present study) than in the model examined by Ma et al. 
(APPswe/PSEN1dE9 mice) and, hence, neurological impairments in the 5XFAD model 
may generally be less accessible to amelioration than those in APPswe/PSEN1dE9 
mice. One exception to the notion that the elF2α+/S51A genotype did not influence 
5XFAD phenotypes was the observation of restored motor hyperactivity in 
5XFAD;elF2α+/S51A mice. Elevated motor activity levels are a consistent feature of AD 
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rodent models (Dodart et al., 1999; Filali et al., 2011; Holcomb et al., 1998; Holcomb et 
al., 1999) and may also be observed in human individuals affected by the disorder 
(White et al., 2004). Alzheimer’s disease is associated with a profound degeneration of 
cholinergic neurons in the basal forebrain (Cullen and Halliday, 1998; Jope et al., 1997; 
Vogels et al., 1990; Whitehouse et al., 1982). Given the role of basal forebrain 
cholinergic neurons in the regulation of motor activity levels (ablation of basal forebrain 
cholinergic nuclei, as well as anti-cholinergic pharmacological interventions increase 
motor activity in rats (Whishaw et al., 1985), we asked whether the elF2αS51A allele 
might restore hyperactivity by rescuing basal forebrain cholinergic neuron loss in 
5XFAD mice. Our stereological analyses showed, however, no significant reduction of 
ChAT-immunoreactive neurons in the MS and VDB of 5XFAD mice, indicating that 
frank loss of cholinergic neurons was limited in the model at the age assessed. 
Nevertheless, immunoblot analyses were sensitive enough to pick up clear 5XFAD-
related reductions in ChAT expression in one of the target areas of basal forebrain 
cholinergic nuclei, namely the hippocampus, which is consistent with prior studies in 
transgenic AD mouse models (Bellucci et al., 2006; Boncristiano et al., 2002; 
Christensen et al., 2010; Devi and Ohno, 2010; Perez et al., 2007). 5XFAD and 
5XFAD;elF2α+/S51A mice did not differ significantly in their hippocampal ChAT levels, 
indicating that the elF2αS51A allele did not rescue the aberrant cholinergic system of 
5XFAD mice. Future studies should further assess the possible mechanistic 
underpinnings of the elF2αS51A effect on 5XFAD-related motor hyperactivity. In 
conclusion, our study revealed few effects of the elF2α+/S51A genotype on disease 
progression in the 5XFAD mouse model of Alzheimer’s disease (with the exception of a 
possible amelioration of 5XFAD-related motor hyperactivity). Future studies need to 
further elaborate on the specific conditions, under which a 5XFAD genotype may be 
associated with elF2α hyperphosphorylation, as well as elevated BACE1 levels.  
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Figure 1. The elF2αS51A mutation had no measurable effects on elF2α 
phosphorylation and APP processing. Shown are representative immunoblots of p-
eIF2 and total eIF2 (A), human APP and total APP (B), -CTF and ß-CTF (C), 
BACE1 (E), all prepared from hippocampal homogenates, along with the respective 
quantitative data from densitometric analyses (n = 5-7 mice per group). (D) 
Concentrations of abundant Aß-species, Aß40 and Aß42, in 5XFAD hippocampal 
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homogenates were determined using enzyme-linked immunosorbent assays. All data are 
presented as mean ± SEM. Data were analyzed using 2-way ANOVAs with the 
between-subjects factors 5XFAD genotype / elF2α genotype (effect of 5XFAD 
transgenes; effect of elF2α genotype; 5XFAD x elF2α interaction) and t-tests (5XFAD 
vs. 5XFAD;elF2αS51A) as appropriate. Statistically significant differences (P < 0.05) are 
denoted by bold font. 
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Figure 2. The elF2αS51A had limited effects on most neurological phenotypes, but 
restored hyperactivity in 5XFAD mice. (A): Hindlimb clasping scores, as assessed in 
the tail suspension test (n = 6-12 mice per group). (B): Latencies to fall in the context of 
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a wire hang test (n = 8-13 mice per group). (C): Activity suppression ratios in a context 
fear conditioning paradigm (n = 6-12 mice per group). (D–G): Results of an assessment 
of spatial learning and memory in the Morris water maze (n = 6-12 mice per group). 
(D): Escape latencies during training trials. (E,F): Quadrant occupancy (E) and target 
crossings (F) measures obtained during a probe tial given after the completion of 
training day 7. For each genotype, bars represent (from left to right): target quadrant, 
opposite quadrant, adjacent right quadrant, adjacent left quadrant. (G): Results of an 
extended swim path analysis: For each group, the proportion of animals in the 
respective search categories is plotted against training trial. (H,I): Distance travelled in 
two independent open field experiments performed at 8 months (H; n = 8-13 mice per 
group) and 11 months of age (I; n = 6-11 mice per group), respectively. Data were 
analyzed using 2-way ANOVAs with the between-subjects factors 5XFAD genotype 
and elF2α genotype (A–C,H,I) or using 3-way ANOVAs with the between-subjects 
factors 5XFAD genotype and elF2α genotype and the within-subjects factor trial (D) or 
quadrant (E,F). Statistically significant differences (P < 0.05) are denoted by bold font. 
For additional information regarding the results of statistical analyses, see main text. 
Bar and line graphs show means ± SEM. 
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Figure 3. EEG recordings revealed non-convulsive seizure activity in the motor 
cortex of animals carrying the 5XFAD transgenes and/or the elF2α+/S51A allele. 
Radiotelemetric recordings from the primary motor cortex (M1) of wild-type, 5XFAD, 
5XFAD;elF2α+/S51A and elF2α+/S51A mice (n = 3-6 mice per group). Wild-type mice did 
not exhibit seizure activity, whereas all other genotypes showed episodes of spike, poly-
spike and spike-wave activity. Shown are example traces, as well as a quantification of 
the number of seizure episodes and the number of spikes, respectively. Bar graphs show 
mean +/- SEM. 
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Supplement 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 1. The cholinergic system was not involved in the 
elF2α+/S51A-related restoration of hyperactivity in 5XFAD mice. (A) Shown are 
micrographs of ChAT-immunoreactive neurons in the basal forebrain of wild-type, 
5XFAD, 5XFAD;elF2α+/S51A and elF2α+/S51A mice. Scale bar = 150 μm. Stereological 
quantification of ChAT-immunoreactive neurons in the MS and VDB of the basal 
forebrain demonstrated no significant differences between the four groups of mice (n = 
3 mice per group). (B) Shown are immunoblots of ChAT from hippocampal 
homogenates of wild-type, 5XFAD, 5XFAD;elF2α+/S51A and elF2α+/S51A mice (n = 5-7 
mice per group). Data were analyzed using 2-way ANOVAs with the between-subjects 
factors 5XFAD genotype and elF2α genotype. Statistically significant differences (P < 
0.05) are denoted by bold font.  Bar graphs show mean ± SEM.  
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Supplementary Figure 2. The elF2αS51A allele had limited effects on transcriptional 
dysregulation in 5XFAD mice. Differentially regulated transcripts (unadjusted p < 
0.05) with a fold change higher than 1.6 were subjected to hierarchical clustering to 
visualize gene expression changes between groups (n = 3 mice per group).  
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Supplementary Table Legends 
 
Supplementary Table 1.  A gene ontology analysis revealed a significant enrichment 
of immune-related transcripts in gene set differentially expressed in 5XFAD 
hippocampus. 
 
 Enrichment Score: 19.126206534555482       
Term Count PValue Fold Enrichment 
glycoprotein 80 2,24E-23 2,961042774 
disulfide bond 63 2,64E-20 3,434502443 
glycosylation site:N-linked (GlcNAc...) 76 6,78E-20 2,730986068 
signal 68 1,00E-19 3,081638523 
signal peptide 68 2,85E-18 2,870982381 
disulfide bond 60 1,53E-17 3,15814549 
        
Enrichment Score: 7.52946739972749       
Term Count PValue Fold Enrichment 
GO:0005764~lysosome 16 9,90E-11 9,515476363 
GO:0000323~lytic vacuole 16 1,07E-10 9,462018631 
GO:0005773~vacuole 16 6,84E-10 8,2967454 
lysosome 12 1,08E-08 11,05764411 
mmu04142:Lysosome 12 1,61E-07 8,086894587 
hydrolase 18 0,05278226 1,601912225 
        
Enrichment Score: 5.619809905239803       
Term Count PValue Fold Enrichment 
topological domain:Extracellular 51 6,36E-13 2,901109156 
topological domain:Cytoplasmic 52 1,59E-09 2,315137268 
transmembrane region 63 2,63E-08 1,896390439 
membrane 72 4,73E-08 1,741488245 
GO:0005886~plasma membrane 50 4,46E-06 1,832607195 
transmembrane 64 6,67E-06 1,635015533 
receptor 29 0,0107878 1,598031624 
GO:0016021~integral to membrane 63 0,05797149 1,176457745 
GO:0031224~intrinsic to membrane 63 0,11288155 1,135369339 
        
Enrichment Score: 4.99067817222587       
Term Count PValue Fold Enrichment 
GO:0006955~immune response 30 8,57E-18 7,601765853 
GO:0006952~defense response 29 1,69E-17 7,825762201 
GO:0002684~positive regulation of immune 
system process 20 5,55E-15 11,57283757 
GO:0048002~antigen processing and 
presentation of peptide antigen 11 2,85E-13 35,53825536 
GO:0050778~positive regulation of immune 
response 16 2,95E-13 14,20543726 
GO:0002252~immune effector process 15 2,61E-12 13,95684211 
GO:0002443~leukocyte mediated immunity 13 9,67E-12 17,1817185 
GO:0002478~antigen processing and 
presentation of exogenous peptide antigen 9 1,42E-11 43,61513158 
GO:0002449~lymphocyte mediated immunity 12 3,26E-11 18,60912281 
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GO:0048584~positive regulation of response to 
stimulus 16 3,36E-11 10,28128332 
GO:0019884~antigen processing and presentation 
of exogenous antigen 9 8,01E-11 36,09528131 
GO:0016064~immunoglobulin mediated immune 
response 11 1,00E-10 20,63511602 
GO:0002250~adaptive immune response 12 1,01E-10 16,81547242 
GO:0002460~adaptive immune response based on 
somatic recombination of immune receptors built 
from immunoglobulin superfamily domains 12 1,01E-10 16,81547242 
GO:0019724~B cell mediated immunity 11 1,39E-10 19,99026864 
GO:0019882~antigen processing and presentation 11 1,35E-09 15,99221491 
GO:0002699~positive regulation of immune effector 
process 8 4,79E-08 22,6940522 
GO:0002821~positive regulation of adaptive immune 
response 7 2,07E-07 26,26287493 
GO:0002824~positive regulation of adaptive immune 
response based on somatic recombination of 
immune receptors built from immunoglobulin 
superfamily domains 7 2,07E-07 26,26287493 
GO:0002474~antigen processing and presentation 
of peptide antigen via MHC class I 6 2,35E-07 41,0495356 
GO:0009897~external side of plasma membrane 13 2,44E-07 7,127314815 
GO:0002822~regulation of adaptive immune 
response based on somatic recombination of 
immune receptors built from immunoglobulin 
superfamily domains 8 3,02E-07 17,55577623 
GO:0002819~regulation of adaptive immune 
response 8 3,02E-07 17,55577623 
GO:0002708~positive regulation of lymphocyte 
mediated immunity 7 4,45E-07 23,26140351 
GO:0002705~positive regulation of leukocyte 
mediated immunity 7 4,45E-07 23,26140351 
GO:0002697~regulation of immune effector process 9 5,03E-07 12,61160431 
GO:0009986~cell surface 15 5,77E-07 5,426028725 
GO:0002706~regulation of lymphocyte mediated 
immunity 8 7,21E-07 15,50760234 
GO:0050766~positive regulation of phagocytosis 6 9,65E-07 31,72009569 
GO:0002703~regulation of leukocyte mediated 
immunity 8 1,25E-06 14,31470985 
GO:0050764~regulation of phagocytosis 6 1,54E-06 29,07675439 
GO:0006909~phagocytosis 7 3,07E-06 16,96144006 
transmembrane protein 14 3,70E-06 5,075639919 
GO:0019864~IgG binding 4 4,24E-06 103,96 
GO:0006911~phagocytosis, engulfment 5 4,69E-06 41,53822055 
GO:0045576~mast cell activation 5 4,69E-06 41,53822055 
GO:0042590~antigen processing and presentation 
of exogenous peptide antigen via MHC class I 4 5,95E-06 93,04561404 
GO:0045807~positive regulation of endocytosis 6 8,07E-06 21,14673046 
GO:0002495~antigen processing and presentation 
of peptide antigen via MHC class II 5 1,09E-05 34,20794634 
GO:0019886~antigen processing and presentation 
of exogenous peptide antigen via MHC class II 5 1,09E-05 34,20794634 
GO:0002504~antigen processing and presentation 
of peptide or polysaccharide antigen via MHC class 
II 5 1,76E-05 30,60710988 
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GO:0032403~protein complex binding 7 2,57E-05 11,81363636 
GO:0019865~immunoglobulin binding 4 6,77E-05 47,25454545 
GO:0051130~positive regulation of cellular 
component organization 8 6,92E-05 7,818959163 
GO:0030100~regulation of endocytosis 6 7,07E-05 13,68317853 
GO:0031349~positive regulation of defense 
response 6 7,77E-05 13,42004049 
GO:0002712~regulation of B cell mediated immunity 5 8,75E-05 20,76911028 
GO:0002889~regulation of immunoglobulin 
mediated immune response 5 8,75E-05 20,76911028 
GO:0002864~regulation of acute inflammatory 
response to antigenic stimulus 4 9,46E-05 42,29346093 
GO:0002883~regulation of hypersensitivity 4 9,46E-05 42,29346093 
GO:0002714~positive regulation of B cell mediated 
immunity 4 1,25E-04 38,76900585 
GO:0002891~positive regulation of immunoglobulin 
mediated immune response 4 1,25E-04 38,76900585 
GO:0001817~regulation of cytokine production 8 1,60E-04 6,841589267 
mmu05322:Systemic lupus erythematosus 8 1,99E-04 6,436507937 
GO:0001803~regulation of type III hypersensitivity 3 2,15E-04 116,3070175 
GO:0001805~positive regulation of type III 
hypersensitivity 3 2,15E-04 116,3070175 
GO:0002861~regulation of inflammatory response to 
antigenic stimulus 4 2,55E-04 31,01520468 
GO:0042742~defense response to bacterium 7 2,58E-04 7,82835695 
GO:0002673~regulation of acute inflammatory 
response 4 3,11E-04 29,07675439 
GO:0009617~response to bacterium 8 3,17E-04 6,121421976 
igg-binding protein 3 3,30E-04 99,51879699 
GO:0019763~immunoglobulin receptor activity 3 3,41E-04 97,4625 
GO:0060627~regulation of vesicle-mediated 
transport 6 6,30E-04 8,615334633 
GO:0001912~positive regulation of leukocyte 
mediated cytotoxicity 4 7,17E-04 22,15371763 
GO:0031343~positive regulation of cell killing 4 7,17E-04 22,15371763 
GO:0006897~endocytosis 8 0,00105586 5,002452367 
GO:0010324~membrane invagination 8 0,00105586 5,002452367 
immunoglobulin receptor 3 0,00113768 56,867884 
GO:0001796~regulation of type IIa hypersensitivity 3 0,00147024 49,84586466 
GO:0001798~positive regulation of type IIa 
hypersensitivity 3 0,00147024 49,84586466 
GO:0001810~regulation of type I hypersensitivity 3 0,00147024 49,84586466 
GO:0002888~positive regulation of myeloid 
leukocyte mediated immunity 3 0,00147024 49,84586466 
GO:0002892~regulation of type II hypersensitivity 3 0,00147024 49,84586466 
GO:0002894~positive regulation of type II 
hypersensitivity 3 0,00147024 49,84586466 
GO:0032101~regulation of response to external 
stimulus 6 0,00162814 6,978421053 
GO:0001910~regulation of leukocyte mediated 
cytotoxicity 4 0,00169061 16,61528822 
 
GO:0031341~regulation of cell killing 4 0,00169061 16,61528822 
GO:0002885~positive regulation of hypersensitivity 3 0,00194941 43,61513158 
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GO:0002866~positive regulation of acute 
inflammatory response to antigenic stimulus 3 0,00194941 43,61513158 
GO:0016044~membrane organization 9 0,00211085 3,891312855 
GO:0001916~positive regulation of T cell mediated 
cytotoxicity 3 0,00249245 38,76900585 
GO:0002675~positive regulation of acute 
inflammatory response 3 0,00249245 38,76900585 
GO:0002863~positive regulation of inflammatory 
response to antigenic stimulus 3 0,00309825 34,89210526 
GO:0001914~regulation of T cell mediated 
cytotoxicity 3 0,00376572 31,72009569 
domain:Ig-like C2-type 1 6 0,00387581 5,736073553 
domain:Ig-like C2-type 2 6 0,00400537 5,691949911 
GO:0002711~positive regulation of T cell mediated 
immunity 3 0,00449379 29,07675439 
GO:0006910~phagocytosis, recognition 3 0,00449379 29,07675439 
GO:0051050~positive regulation of transport 6 0,00490073 5,409628723 
GO:0002886~regulation of myeloid leukocyte 
mediated immunity 3 0,00528139 26,84008097 
GO:0002709~regulation of T cell mediated immunity 3 0,00900633 20,5247678 
GO:0050727~regulation of inflammatory response 4 0,01090708 8,615334633 
GO:0050729~positive regulation of inflammatory 
response 3 0,0136022 16,61528822 
GO:0001819~positive regulation of cytokine 
production 4 0,01386451 7,885221528 
GO:0016192~vesicle-mediated transport 10 0,01714017 2,517467912 
GO:0032680~regulation of tumor necrosis factor 
production 3 0,02047792 13,42004049 
GO:0032103~positive regulation of response to 
external stimulus 3 0,03757426 9,692251462 
IPR013151:Immunoglobulin 5 0,04086841 3,838750881 
GO:0051240~positive regulation of multicellular 
organismal process 5 0,04433638 3,727789024 
GO:0008037~cell recognition 3 0,05845242 7,585240275 
domain:Ig-like C2-type 3 3 0,15227306 4,302055165 
GO:0005783~endoplasmic reticulum 6 0,90268751 0,754587507 
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Abstract 
Alzheimer’s disease (AD) is an age-related neurodegenerative disorder characterized by 
impairment of memory function. Eurhythmic activity in the brain is mandatory for 
cognitive function and recent evidence suggests that accumulation of soluble amyloid-
beta (Aß) in AD patients induces reorganisation in hippocampal and other neuronal 
networks resulting in an imbalance of inhibition and excitation. 5XFAD mouse model 
was analysed and conmpared with wild type controls for functional interdependence 
between seizure activity and hippocampal theta oscillations by using simultaneous 
video-electroencephalogram (EEG) monitoring, seizure scoring and time-frequency 
analysis. Seizure staging revealed that 5XFAD mice exhibited non-convulsive seizure 
activity of different severity whereas controls did not. 5XFAD mice displayed a 
significant increase in theta activity from the light to dark phase during non-motor 
activity. In addition, we observed a reduction in mean theta frequency in 5XFAD mice 
compared to controls that was again most prominent during non-motor activity. 
Transcriptome analysis of hippocampal probes and subsequent qPCR validation 
revealed an upregulation of PLCδ4 that might be indicative of enhanced muscarinic 
signalling. The latter was shown to be involved in both ictogenesis and theta genesis. 
Our study suggests that dysfunction of the muscarinic signaling contributes to 
hippocampal dysrhythmicity and seizure activity in 5XFAD mice thus providing a 
potent target cascade in AD treatment. 
 
Key words: 5XFAD, hippocampus, microarray, neurodegeneration, seizure, theta  
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Introduction 
Alzheimer’s disease is an irreversible, progressive brain disorder slowly destroying 
learning and memory skills. The histopathology of Alzheimer’s disease (AD) is 
characterized by two hallmark lesions, extracellular amyloid-ß plaques made of the Aß 
peptide, and intra cellular neurofibrillary tangles (NFT) composed of 
hyperphosphorylated tau protein. In addition to the presence of plaques and tangles in 
the brain, considerable neuron loss is also a cardinal feature of AD, but the mechanisms 
of neural cell death still remain unclear. Importantly, familial AD (FAD) mutations in 
the genes for amyloid precursor protein (APP), presenilin 1 (PSEN1), and presenilin 2 
(PSEN2) implicate Aß as an initiating factor in AD pathogenesis. These FAD mutations 
increase the production of Aß42 from APP, which is sequentially cleaved by the ß- and 
γ-secretase enzymes to release the peptide. The Aß42 fragment plays a central early role 
in the pathophysiology of AD that ultimately leads to neuronal cell loss, e.g. in the 
septum, entorhinal cortex and hippocampus (Scott et al., 2012; Yamaguchi et al., 1989) 
and dementia (Selkoe, 2002; Selkoe and Schenk, 2003). 
Transgenic mouse models of AD exhibiting homology, isomorphism and predictivity 
have proven to be valuable tools in investigating the etiopathogenesis of the disease 
(Ashe, 2001; Duff and Suleman, 2004; Eriksen and Janus, 2007; Glenner et al., 1984; 
Glenner and Wong, 1984; Ohno et al., 2007; Torres-Aleman, 2010). Studies on various 
AD mouse models exhibited dysregulation of the ß-site APP cleaving enzyme 1 
(BACE1) that is ultimately responsible for the generation of Aß plaques (Devi and 
Ohno, 2013; Sinha and Lieberburg, 1999; Vassar et al., 1999). Therefore, increased 
translation of BACE1 leads to an increased number of plaques and finally to a 
disruption of neuronal functioning within the hippocampus (Oakley et al., 2006; Ohno 
et al., 2004). Among different AD models, the 5XFAD model is a most progressive, 
growth retarded AD model expressing multiple FAD mutations that additively increase 
Aß42 production: three human APP mutations (Swedish mutations: K670N, M671L; 
Florida mutation: I716V; London mutation: V717I) and two mutant PSEN1 (M146L, 
L286V). Individually, each FAD mutation enhances Aß42 generation, but together they 
act synergistically in the transgenic mouse to predominantly accumulate Aß42. 5XFAD 
mice exhibit intraneuronal Aß42 accumulation at 1.5 months, amyloid deposition at 2 
months, and memory deficits by 4 months of age (Crouzin et al., 2013; Games et al., 
1995; Goutagny and Krantic, 2013; Oakley et al., 2006; Rockenstein et al., 1995). 
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Furthermore, the 5XFAD model is one of a few known mouse models that exhibits 
significant neuronal loss in the hippocampus that correlates with accumulation of Aß 
plaques (Casas et al., 2004; Jawhar et al., 2012; Oakley et al., 2006). In the cortex the 
neuronal loss was reported to be predominately related to layer 5 (Eimer and Vassar, 
2013; Oakley et al., 2006). Quantification of layer 5 neurons in 12 months old 5XFAD 
mice confirmed neuronal loss in this brain region (Eimer and Vassar, 2013; Oakley et 
al., 2006). However, the overall number of neurons in the frontal cortex and 
hippocampal CA1 region remained unchanged compared with age-matched wild type 
(WT) mice (Jawhar et al., 2012). Whereas cortical layer 5 neurons accumulate 
considerable amounts of Aß, CA1 neurons did not show high levels of transgenic APP 
expression compared to WT animals. It’s noteworthy that there is only a weak 
correlation between plaque density and hippocampus-related memory deficits in e.g. 8 
months old 5XFAD mice (Kaczorowski and Disterhoft, 2009). Thus, cortical plasticity 
is impaired prior to hippocampal-dependent learning and memory deficits in 6 month-
old 5XFAD mice (Casas et al., 2004; Games et al., 1995; Ohno et al., 2004). The motor 
phenotype in 5XFAD mice correlates with abundant spinal cord pathology resulting in 
impaired performance in sensory-motor tasks as a consequence of axonopathy. 
Interestingly, 12 months old 5XFAD were reported to exhibit less anxiety, but normal 
locomotor behaviour (Jawhar et al., 2012). In addition, efforts were carried out to 
characterize the transcription and expression profile in 5XFAD mice compared to WT. 
Using quantitative mass spectrometry to investigate proteome-wide changes in 4 
months old 5XFAD mice (Kaczorowski and Disterhoft, 2009), alterations were 
predominantly identified in ApoE, ApoJ (clusterin), and nicastrin expression. NRF2 and 
p53 transcriptional pathways were activated, as well as IGF-1 signaling. Furthermore, 
various neurological glial marker proteins and factors implicated in neurological 
disorders such as AD, Parkinson’s disease, Huntington’s disease, and amyotrophic 
lateral sclerosis were affected (Hong et al., 2013). Transcriptome analysis has also been 
carried out for the frontal cortex and cerebellum of 7 week old 5XFAD mice (Kim et al., 
2012). 
Although different neuropathological changes have been well described previously, 
direct effects on systemic electrophysiological alterations in AD have received less 
attention in the past. Currently, the impact of brain oscillation analysis as a novel tool in 
early diagnosis and prediction of disease progression is strongly discussed as functional 
impairments in AD can occur even without any significant neuronal loss and therefore 
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could be independent of plaque formation (Blanchet, 2003; Martino and Giovannoni, 
2004; Palop et al., 2006; Palop et al., 2007; Palop and Mucke, 2009). Recent studies 
showed that altered hippocampal oscillatory activity correlates with an increase of Aß 
level and the appearance of plaques (Buzsaki, 2002; Colom, 2006; Scott et al., 2012) 
but slight changes in hippocampal and cortical network activity can also occur much 
earlier prior to clinical onset of AD (Chin and Scharfman, 2013; Minkeviciene et al., 
2009; Palop et al., 2006; Palop et al., 2007; Palop and Mucke, 2009). Alterations in 
network activities are reorganised in AD by an early imbalance of excitation and 
inhibition that elites overall changes in theta activity as a hallmark of hippocampal 
functioning (Goutagny and Krantic, 2013; Scott et al., 2012; Verret et al., 2012). These 
alterations due to Aß-induced neuronal hyperexcitability (Minkeviciene et al., 2009) are 
accompanied by decreased GABAergic transmission within the hippocampus and can 
trigger seizure activity (Hauser et al., 1986; Larner, 2010; Mendez and Lim, 2003; 
Morrison and Hof, 1997; Price et al., 2001; Romanelli et al., 1990; Scarmeas et al., 
2009; Terry et al., 1991). Neurons that are early affected in AD pathogenesis are those 
of the septohippocampal circuitry, including cholinergic, GABAergic and glutamatergic 
cells (Auld et al., 2002; Cullen and Halliday, 1998; Gutierrez-Lerma et al., 2013; 
Ikarashi et al., 2004; Klingner et al., 2003; Kordower et al., 2001; Luth et al., 2003; 
Palhalmi et al., 2004; Reich et al., 2005).  Interestingly, various mouse models of AD 
can exhibit opposing alterations in theta rhythmicity, i.e. a number of them were 
reported to present cognitive decline associated with increased theta activity (Babiloni 
et al., 2007; Blanchet, 2003; Cummins et al., 2008; Pena-Ortega and Bernal-Pedraza, 
2012) whereas others displayed reduced theta rhythm (Cummins et al., 2008). The 
reason for either enhanced or decreased theta activity - remains largely unknown. 
Though, recent studies have gained substantial insight into the etiopathogenesis of AD, 
we are still missing detailed information about how septohippocampal networks 
functionally disintegrate theta rhythm and epilepsy in AD. In this study we combined 
seizure analysis, time-frequency based theta analysis and transcriptome data from 
5XFAD mice to detect a missing link in AD phenomenology. Our study suggests that 
alterations in muscarinic signalling can account for complex changes in hippocampal 
theta and exacerbation of seizure activity in the 5XFAD model of AD.  
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Material and Methods 
Study Animals 
This study was performed in Tg (APPSwFlLon,PSEN1*M146L*L286V)6799Vas 
(5XFAD) transgenic mice with a B6/SJL background overexpressing mutant forms of 
human APP (the Swedish mutations: K670N, M671L; the Florida mutation: I716V; the 
London mutation: V717I) and mutant PSEN1 (M146L, L286V). Five WT controls 
(mean body weight: 35.32 ± 2.40 g, mean age: 74.00 ± 5.76 weeks, 4 ♂, 1 ♀) and five 
5XFAD mice (mean body weight: 24.89 ± 1.40 g, mean age: 72.20 ± 2.85 weeks, all ♂) 
were used in this study. All mice were housed in groups of 3-4 in clear Macrolon cages 
type II with ad libitum access to drinking water and standard food pellets. Using 
ventilated cabinets (Model 9AV125P, Techniplast, Germany), mice were maintained at 
a temperature of 21 ± 2 °C, 50 – 60% relative humidity, and on a conventional 12 h 
light/dark cycle with the light cycle beginning at 5:00 AM for spontaneous epidural and 
deep, intracerebral EEG recordings. All animal procedures were performed according to 
guidelines of the German Council on Animal Care and all protocols were approved by 
the local institutional and national committee on animal care (Landesamt für Natur, 
Umwelt und Verbraucherschutz, LANUV, Germany).The authors further certify that all 
animal experimentation was carried out in accordance with the European Communities 
Council Directive of 24 November 1986 (86/609/EEC). Specific effort was made to 
minimize the number of animals used and their suffering. 
 
Stereotaxic EEG electrode implantation and radiotelemetric EEG recordings 
Mice were anesthetized using ketamine / xylazine (100/10 mg/kg ip.) and the 
radiotelemetry transmitter (TL11M2-F20-EET 2-channel transmitter, Data Science 
International (DSI), specifications: weight 3.9 g, volume 1.9 cc, input voltage range ± 
1.25 mV, channel bandwidth 1 - 50 Hz) was implanted into a subcutaneous pouch on 
the back of the animals. The EEG electrodes of both transmitter channels were 
stereotaxically positioned using a computerized 3D stereotaxic StereoDrive
®
 (Neurostar, 
Germany). The differential epidural electrode of channel 1 targeting the primary motor 
cortex (M1) was positioned at the following coordinates referring to bregma 
craniometric landmark: (+)-lead cranial +1 mm, lateral of bregma 1.5 mm (left 
hemisphere). For deep, intracerebral brain recordings targeting the hippocampal CA1 
region the differential electrode of channel 2 was positioned as follows: (-)-lead, caudal 
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-2 mm, lateral of bregma 1.5 mm (right hemisphere), dorsoventral (depth) 1.5 mm. For 
both channels, epidural reference electrodes were placed on the cerebellar cortex at: 
bregma -6 mm, lateral of bregma 1 mm (left hemisphere) and bregma -6 mm, lateral of 
bregma 1 mm (right hemisphere), respectively (Fig. 1) Electrodes were fixed using glas 
ionomer cement (Kent Express, UK) and the scalp was closed using over and over 
sutures (Ethilon, 6-0). To avoid hypothermia, supplemental warmth is given to the 
animal during the whole surgery procedure. A detailed description of the implantation 
procedure is given in (Weiergraber et al., 2005). For postoperative pain management 
animals were administered carprofen (5 mg/kg sc., Rimadyl, Parke-Davis/Pfizer, 
Germany). Animals were allowed to recover for 10 days prior to subsequent recordings. 
This recovery period is based on the observation that 10 days post-surgery no difference 
in physiological parameters between transmitter implanted, non-implanted and sham-
operated animals could be detected (Kramer and Kinter, 2003).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Stereotaxic EEG electrode placement. A) One epidural, differential 
electrode is placed on the motor (M1) cortex, an additional intrahaippocampal (CA1) 
differential electrode is placed in the CA1 region of the hippocampus. Both 
pseudorefernce electrodes are localized on the cerebellum. B) Coronal section (scheme) 
illustrating the localisation of the deep, intracranial electrode for recording the 
electrohippocamogram. C) Close-up of the deep EEG electrode, the sensing lead of the 
radiofrequency transmitter and their arrangement on top of the murine skull. 
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Validation of EEG electrode placement 
To verify the correct electrode placement targeting the CA1 region, brains were 
extirpated post mortem and fixed in 4% paraformaldehyde. Afterward, brains were cut 
to 60 µm slices using a Vibroslice Tissue Cutter EMS 5000-MZ (Campden Instruments 
Limeted) and hematoxylin-stained for visualization of the branch canal. Animals with 
false EEG electrode placement were removed from the study. 
 
EEG data acquisitions 
Ten days after radiotransmitter implantation, simultaneous video-EEG recordings from 
the motor cortex (M1) and the hippocampal CA1 region were performed for 48 h using 
Dataquest ART 4.2 software (DSI) at a sampling rate of 500 Hz with no a priori filter 
cut-off.  
 
Electroencephalographic and behavioural seizure analysis 
For further analysis data were exported to Neuroscore 2.1 (DSI). Qualitative and 
quantitative seizure analysis was performed using the Neuroscore seizure detection 
module. Spike parameters including dynamic and absolute threshold, spike duration and 
spike intervals were adapted for different seizure protocols. Dynamic thresholds were 
based on multiplication of RMS values of the EEG signals one minute prior to EEG 
segments being analyzed. The threshold ratio (minimum threshold) was defined by 2 
while the maximum ratio was defined as 15. The minimum amplitude value of spikes 
was 100 μV for the dynamic range. In case of the absolute threshold the maximum 
amplitude was fixed at 1000 μV with a threshold value of 200 μV. In both seizure 
protocols the minimum spike duration was determined at 1 ms and the maximum spike / 
short/slow-wave duration at 100 ms. Spike trains were detected with a minimum train 
duration of 0.5 s including at least 4 individual spikes. Spike intervals within a train 
were ranging between 0.05 and 0.3 s. The interval between individual spike trains was 
determined at 1 s. Seizure protocols contained total number of seizure episodes and 
spikes, spike frequency, total spike train duration, shortest and longest spike train 
duration. Data were calculated and plotted throughout the figures as mean ± standard 
error of the mean (SEM). Significance was calculated using Student’s t-test which 
included pretesting for normal distributions via the Kolmogorov-Smirnov test.  
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Urethane induced theta oscillations 
Urethane (Sigma, Germany) was freshly dissolved in 0.9% NaCl and systemically (ip.) 
administered at 800 mg/kg to induce atropine-sensitive type II theta oscillations. Four 
control mice (mean body weight: 32.98 ± 0.65 g, mean age: 77.00 ± 2.31 weeks, 3 ♂, 1 
♀) and four 5XFAD animals (mean body weight: 25.52 ± 1.61 g, mean age: 73.75 ± 
3.09 weeks, all ♂) were used for this approach. CA1 recordings under baseline 
conditions (30 min duration) and under urethane (30 min duration 15 to 45 min post 
injection) were used for analysis of hippocampal theta oscillations.  
 
EEG data analysis 
Complex EEG analysis was performed for spontaneous 48 h recordings at a sampling 
rate of 500 Hz. Data segments with a length of 60 min each were extracted from the 48 
h recording time. Data segments were analyzed using complex Morlet wavelets to 
calculate both frequency and amplitude of oscillations. The complex Morlet wavelet is 
deﬁned by Ψ(x) = (πb)(–1/2) exp(2πicx) exp(-x2/b) where b is the bandwidth parameter, c 
the center frequency, and i the imaginary unit (Kronland-Martinet et al., 1987). This 
wavelet or similar ones have often been applied in literature to study EEG data, as they 
guarantee optimal resolution in both frequency and time (Kronland-Martinet et al., 
1987; Montgomery and Buzsaki, 2007). In our case, the bandwidth parameter and 
centre frequency were both set to 3 in order to particularly weight the frequency 
resolution to distinguish frequency differences on the 0.1 Hz level, but not to neglect a 
sufﬁcient time resolution. EEG data were analyzed in the frequency range of 0.2–12 Hz 
with a step size of 0.1 Hz, thus including the typical delta, theta, and alpha frequency 
ranges (Fig.2). In order to apply the wavelet technique for extraction of theta-oscillatory 
segments, we developed a task-adjusted detection criterion. This theta detection method 
imitates the standard visual inspection of theta oscillations and is substantially based on 
a complex elaboration of the frequency architecture of theta activity. For details see 
Müller et al. 2012 (Muller et al., 2012). Theta oscillations are defined, where the ratio of 
the maximum amplitude in the theta-alpha range (4-12 Hz) is at least two times the 
maximum amplitude in the upper delta frequency range (2–3.9 Hz) for a time window 
of 2.5 s. This time length is suited to precisely analyze theta activity (Goutagny and 
Krantic, 2013). Some extracted theta segments do not correspond to the normal theta 
activity, but show times where mice are eating or scratching which was controlled via 
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video analysis of the mice. To eliminate those segments, an algorithm was developed 
and tested for a valid application. Theta segments with mean frequency lower than 5 Hz 
or higher than 10 Hz, where the mean frequency changes only slightly over time, are 
excluded. Finally, cleaned EEG segments identiﬁed as theta oscillation epochs were 
statistically analyzed and all data displayed as mean ± SEM. For further analysis, 
additional information about the activity of mice during 48 hours is used to link theta 
activity of the CA1 region to times with and without motor activity. Additionally, we 
divided the 48 hours EEG recordings into a conventional 12 h dark/light cycle with the 
dark cycle beginning at 5:00 PM. All EEG calculations were done using custom-made 
programs in Matlab
®
 (The MathWorks Inc., Version R2012b). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Time-frequency analysis of theta activity in control and 5XFAD mice. A) 
Colour-coded time-frequency plot of extracted theta segments from EEG data. These 
segments were clued together (13 minutes in total) for a better demonstration of the 
oscillatory activity. The y-axis represents the frequency range of 4-12 Hz. B) Mean 
theta frequency (Hz) calculated for the hippocampal theta-alpha band (4-12 Hz). Note, 
that A) and B) display specific episodes of consistent, high amplitude, low frequency 
EEG activity that was proven to be related to behavioural aspects such as grooming, 
scratching or eating based on video analysis. A specific algorithm was defined to 
automatically detect and eliminate these episodes from further evaluation (black bars, 
B). 
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Gene expression profiling using microarray procedure 
Total RNA (250 ng) was prepared from the hippocampi of three control mice (age: 
68.10 ± 0.05 weeks, 2 ♂, 1 ♀) and three 5XFAD animals (age: 68.24 ± 0,75 weeks, 2 
♂, 1 ♀) using RNeasy Lipid Tissue Mini Kit (Qiagen). Microarray experiments were 
carried out using Mouse Exon ST arrays (Affymetrix). Arrays were washed and stained 
according to the manufacturer’s recommendations. Labeled and purified cDNA was 
fragmented (5.5 μg) and subsequently hybridized to the arrays before scanning in a 
GeneChip 3000 7G scanner (Affymetrix). Normalization to the median of all samples, 
background correction as well as statistical analysis was performed with GeneSpringGX 
software (Agilent technologies). An implemented GC-RMA algorithm was applied on 
all chips to summarize probe level information. Microarray data were analyzed using 
unpaired t-tests. An uncorrected significance level p < 0.05 was adopted in all instances. 
Differentially regulated transcripts with a fold change (FC) greater than 1.6 were then 
subjected to hierarchical clustering analysis in order to visualize gene expression 
changes across groups. Array data are available in the GEO database under GSE50521. 
DAVID (Huang et al., 2009) used to carry out gene ontology enrichment analyses in the 
gene set differentially expressed between 5XFAD and WT controls. 
 
RNA extraction and quantitative Real-time PCR (qPCR) 
Quantitative Real-time PCR was used to validate potential gene candidates that 
exhibited transcriptional alterations in microarray analysis. The cDNA synthesis from 
hippocampal RNA (see above) was carried out using anchored-oligo(dt)18 and hexamer 
primer in a two-step RT-PCR approach (Transcriptor First Strand cDNA Synthesis Kit, 
Qiagen) and qPCR reaction protocol was based on LightCycler 480 SYBR Green I 
Master (Roche). The qPCR was performed in a Light Cycler 480 System (Roche) 
thermocycler. The following cycler protocol was used for all primer pairs (Tab. 1): 
95°C (10 min, pre-incubation step); 95°C (10 s, melting step); 60°C (20 s, annealing 
step); 72°C (30 s, extension step), 35 cycles. The specificity of the amplification was 
checked by melting curve analysis and the products were identified by electrophoresis. 
Deionized, nuclease-free water (no cDNA) and total RNA samples (without RT) were 
used as controls and HPRT was used as an internal reference gene. The Ct-values (cycle 
threshold) were calculated using the LightCycler 480 System software. Fold changes 
(FC) of Cacna2d1, Kcnma1, Cacna1e, Prkcb, Plc4, Scn8a, Plc1 and Casp8 gene 
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expression in 5XFAD transgenic mice related to WT controls were calculated according 
to Schmittgen and Livak (2008) (Schmittgen and Livak, 2008).  
 
Statistical analysis 
Further statistical analyses concerning duration, frequency, amplitude of theta segments, 
and comparisons between groups and experimental conditions were done with IBM® 
SPSS® Statistics, Version 22 (IBM Corporation, 2013). The Kolmogorov-Smirnov test 
was used to test for normal distributions. A Student’s t-test was used to detect 
differences between the two groups of the above mentioned parameters. For data that 
does not show a normal distribution, the Mann–Whitney U-test was used instead was 
applied, where we made use of the exact solution. This is necessary, since the 
asymptotic solution overestimates the p-value for small numbers of animals per group. 
For analysis of urethane induced theta oscillations the repeated measures ANOVA with 
within-subjects factor “experimental condition” (baseline vs. post urethane) and 
between-subjects factor “genotype” (control mice vs. 5XFAD mice) was used. The 
Simes-Hochberg “step up” procedure was applied to correct for multiple testing, if 
necessary (Hochberg, 1988). This procedure was utilized at a p-level of 0.05. 
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Results 
Phenotypical characterization 
As reported previously, 5XFAD mice exhibited a reduced body weight in comparison to 
their WT littermates (24.89 ± 1.40 g v. 35.32 ± 2.40 g, p=0.006, n=5; p=0.006). The 
same is true for a characteristic clasping phenotype involving a simultaneous retraction 
of both fore- and hind-paws (Jawhar et al., 2012). 
 
Electrocorticographic characteristics of control and 5XFAD mice 
In this study epidural surface (M1) and deep intrahippocampal CA1 long-term (48 h) 
EEG recordings were obtained in 5XFAD and WT mice (Fig. 3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Electroencephalographic (EEG) characteristics of controls and 5XFAD 
mice. EEGs recorded from the primary motor cortex (M1) as Electrocorticogram 
(ECoG) (A) and hippocampal CA1 region as electrohippocampogram (B) from both 
WT and 5XFAD mice. In the CA1 electrohippocampogram neither controls (BI) nor 
5XFAD mice (BII) exhibited typical ictal discharges / epileptiform graphoelements in 
48 h long-term recordings. Electrocorticographic M1 recording however, exhibited 
subclinical, i.e. electroencephalographic seizure activity in 5XFAD mice of different 
severity (AII) that was not detectable in control mice (AI). 
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EEG recordings were combined with simultaneous video-recordings to detect potential 
movement artefacts and to differentiate convulsive from non-convulsive seizure 
activity. 
Despite the WT mice (Fig. 3AI,BI), 5XFAD mice exhibited seizure activity in the M1 
recording depicting episodes or trains of spike, poly-spike and spike-wave activity (Fig. 
3AII).Video analysis revealed that none of the motor cortex seizures were associated 
with motoric exacerbation thus remaining subclinical or non-convulsive.  
 
Seizure analysis in control and 5XFAD mice 
The seizure phenotype of 5XFAD mice was analysed using simultaneous video-EEG 
recordings for a total duration of 48 h (Fig. 4). None of the WT littermates exhibited 
epileptiform graphoelements according to the automated seizure scoring system 
(Neuroscore 2.1
®
, DSI). In contrast, 5XFAD mice displayed apparent ictal discharges, 
such as spikes, polyspikes and spike-waves. In summary, the total number of seizure 
episodes was 13.00 ± 11.05, the total number of spikes: 51.40 ± 43.37, the spike 
frequency 5.26 ± 1.32 Hz and the total spike train duration: 8.84 ± 7.55 sec (Fig. 4A-D). 
Further seizure parameters in 5XFAD mice included the average spike train duration 
0.51 ± 0.13 sec, the average number of spikes per train 3.22 ± 0.81, the maximum spike 
train duration 0.64 ± 0.19 and the minimum spike train duration 0.46 ± 0.12 sec (Fig. 
4E-H). These seizures turned out to be subclinic or non-convulsive and turned to be 
most prominent in the M1 deflection. No forelimb clonus, no rearing and falling and no 
generalized tonic-clonic seizures were observed. However, a single 5XFAD mouse 
exhibited convulsive tonic-clonic seizures of status-like character with prominent 
interictal spike activity (not shown) and died during the first recovery period. It was 
excluded from further analysis. Interestingly, 5XFAD mice did not show predominate 
ictal discharges in the deep, intra-hippocampal CA1 recording (Fig. 3BII). Disinhibitory 
tendencies as become apparent in our seizure analysis were speculated to be relevant 
also for reduced anxiety in 5XFAD mice (Jawhar et al., 2012). 
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Figure 4: Seizure characteristics in control and 5XFAD mice. Total number of 
seizure episodes (A) and spikes (B), spike frequency (C), total (D) and average (E) 
spike train duration, average number of spikes per train (F) as well as maximum (G) 
and minimum spike train duration (H) are depicted. Parameters were analysed using the 
Neuroscore
®
 Automated Seizure Module (DSI). Whereas 5XFAD mice exhibited ictal 
discharges of highly variable degree, none of the controls displayed epileptiform 
graphoelements. 
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Differential gene expression detected by microarray 
Alzheimer’s disease is associated with considerable transcriptional alterations in key 
brain areas. Gene expression analysis employing Mouse Exon ST arrays (Affymetrix) 
on hippocampal tissue revealed 1421 transcripts differentially regulated between 
5XFAD mice and WT controls. The statistical analysis applied an uncorrected 
significance level of p < 0.05. Array data and further detailed information are available 
in the GEO database under GSE50521. Candidates that are likely to be of interest for 
seizure and theta activity are depicted in Supplementary Tab. 1. Those with FC > 2 are 
listed in Supplementary Tab. 2. Gene ontology analysis revealed that the strongest 
transcriptional alterations belong to immune-response and inflammation related genes 
observed in the context of late-stage cerebral amyloidosis. 
 
Changes in gene expression levels in 5XFAD mice compared WT controls  
We performed qRT-PCR on hippocampus from three WT controls and three 5XFAD 
mice to determine gene expression changes. Among the differentially expressed genes 
in the microarray assay, we chose eight genes for qRT-PCR analysis based on their 
involvement in the theta-genesis pathway. The selected genes and their qPCR primers 
are listed in Tab. 1. Among the eight genes tested, qPCR revealed upregulation of 
Casp8 (FC: 2.0979, Tab. 2) which is likely to be responsible for neuronal cell loss in 
5XFAD mice based on altered regulating of microglia activation through a PKC-δ 
dependent pathway (Burguillos et al., 2011). 
 
 
 
 
 
 
 
Table 1: Sequence of primer pairs used for qRT-PCR. Based on micro-array 
analysis comparing controls and 5XFAD mice eight candidates were chosen that were 
thought to be related to theta or seizure activity. 
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The Scn8a Na
+
 channels as well as Kcnma1 K
+
 channels were not changed in 
transcription. Interestingly, microarray analysis suggested alterations in the muscarinic 
signal transduction pathway including Plcb1, Plcd4, Prkcb, Cacna1e and Cacna2d1 that 
might be relevant for theta oscillations (Muller et al., 2012).  
Validation of these components finally supported an increase in PLCd4 transcript levels 
(FC: 1.6105) whereas no substantial fold change could be detected for the other factors 
(Fig. 5, Tab. 2). 
 
 
 
 
 
 
Table 2: Fold changes in gene expression of 5XFAD transgenic mice compared to 
controls. Calculations were performed according to Schmittgen and Livak (2008).  
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Figure 5: Gene transcription profiles in 5XFAD mice. RNA extracted from the 
hippocampus of control and 5XFAD mice was used for microarray analysis. A selected 
number of candidates which exhibited altered expression profile in microarray analysis 
were further validated using quantitative Real-time PCR (qPCR). Normalized CT 
(log scale) for Cacna2d1, Kcnma1, Cav2.3II-III-loop, Prkcb, Plc4, Scn8a, Plc1 and 
Casp8 are depicted. Note that there turned out to be a minor decrease in PLCb1 
transcript levels but a clear increase in Plcd4 in 5XFAD mice.  
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Intrinsic hippocampal oscillatory activity in WT control and 5XFAD mice 
Prior to analysis of the hippocampal oscillatory behaviour, we analyzed motor activity 
in control and 5XFAD mice as active exploratory behaviour is associated with a 
different type of theta entity as compared to e.g. alert immobility (Fig. 2A,B). 
Movement in the horizontal plane was automatically determined by the recording 
system. The total time of motor activity did not change between controls and 5XFAD 
mice (9.1021 ± 0.7242 min/h v. 9.5924 ± 1.7658 min/h, Fig. 6A). The same hold true 
for motor activity during the light phase (8.1097 ± 1.2257 min/h v. 8.7222 ± 1.3571 
min/h, Fig. 6B) and dark phase (10.0944 ± 1.0526 min/h v. 10.4625 ± 2.5194 min/h, 
Fig. 6C). These results correlate with finding from Jawhar et al., 2012 for exploratory 
and spontaneous locomotor activity in 5XFAD mice aged 9 to 12 months. As expected 
however, there was an increase in motor activity from light to dark phase in both 
genotypes (Fig. 6B,C).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: Motor activity in controls and 5XFAD mice. The radiotelemetry system is 
capable of measuring movement in the horizontal plane as rel. units. 10s epochs were 
categorized in a binary fashion as motor segments or non-motor segments. Motor 
activity was then calculated as [min/h] for the whole observation period (light + dark 
phase, A) and the light (B) and dark phase (C) separately. No difference was observed 
between both genotypes. 
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Based on these findings, alterations in 5XFAD theta architecture cannot be attributed to 
changes in activity pattern. To determine whether hippocampal theta oscillations were 
indeed altered in 5XFAD mice, we performed spontaneous 48 h video-EEG recordings 
from the CA1 region of the hippocampus from both controls and 5XFAD mice. Using a 
time-frequency approach, theta duration, theta frequency and theta amplitude were 
calculated. First, theta duration was calculated for both motor and non-motor activity. 
No significant changes were observed for controls compared to 5XFAD mice during the 
total observation period (5.4418 ± 2.2384 min/h v. 7.3587 ± 0.8902 min/h, Fig. 7A), the 
light phase (5.2910 ± 2.2141 min/h v. 6.0306 ± 1.0558 min/h, Fig. 7B) or the dark 
phase (5.5927 ± 2.2731 min/h v. 8.6868 ± 1.1632 min/h, Fig. 7C). However, data 
suggested that there might be an increase in theta during the dark phase (Fig. 7C). 
During non-motor activity again no significant differences were detected for the total 
duration (3.8852 ± 1.5287 min/h v. 4.8691 ± 0.5677 min/h, Fig. 7D), the light phase 
(3.9122 ± 1.4981 min/h v. 4.0313 ± 0.5944 min/h, Fig. 7E) or the dark phase (3.8583 ± 
1.5605 min/h v. 5.7069 ± 0.6974 min/h, Fig. 7F). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: Characteristics of Theta duration in control and 5XFAD mice. The theta-
alpha band was analysed using a time-frequency approach. Behavioural artefacts were 
removed using an algorithm as described above. Theta-segments (10s) were summed to 
determine theta duration [min/h]. Theta duration was calculated for both genotypes for 
the total observation period (A) and the light (B) and dark (C) phase, respectively. Total 
and phase-specific analysis was also done for non-motor activity (D-F) and motor 
activity (not shown). Mean values suggest an increase in theta duration in 5XFAD mice, 
particularly during the dark phase (C,F). 
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During the dark phase of no motor activity a tendency of increased theta duration was 
observed again, particularly in relation to the light phase. Based on this observation we 
analysed the percentage change of theta from light phase (LP) to dark phase (DP) via 
(LP/DP-1)*100. For the total 48h observation period, a significant trend was observed 
between controls and 5XFAD mice (-5.5515 ± 5.7781 v. -28.7790 ± 10.5690, p = 0.090, 
Fig. 8A), for non-motor activity this change turned out to be significant (5.1135 ± 
4.8816 v. -27.5153 ± 8.9914, p = 0.013, Fig. 8B).  
 
 
 
 
 
 
 
 
 
Figure 8: Percentage change in theta duration during light/dark switch. Data from 
Figure 7 (B,C,E,F) were used to calculate the percentage change in theta duration for 
every individual mouse during the total observation period (48 h, A), during non-motor 
activity (B) and motor activity (not shown). During switch from light to dark cycle there 
turned out to be a statistic trend for theta duration increase in 5XFAD mice (A). Again, 
this effect was most prominent and significant during no motor activity (C) and absent 
during motor activity. 
 
Theta analysis during motor activity did not reveal any statistical differences (light and 
dark: 1.5566 ± 0.7158 min/h v. 2.4896 ± 0.4803 min/h; light: 1.3788 ± 0.7246 min/h v. 
1.9993 ± 0.4987 min/h; dark: 1.7344 ± 0.7550 min/h v. 2.9799 ± 0.7444 min/h). An 
important parameter to be affected during the pathogenesis of Alzheimer’s disease in 
humans is theta frequency. For the total recording period (light and dark phase) and the 
dark phase there was a tendency of reduced theta frequency in 5XFAD mice (7.0439 ± 
0.2821 Hz v. 6.5019 ± 0.1957 Hz, Fig. 9A; 6.7709 ± 0.2537 Hz v. 6.2876 ± 0.2294 Hz, 
Fig. 9C) with a statistical trend during the light phase (7.0923 ± 0.2624 Hz v. 6.4782 ± 
0.1899 Hz, p = 0.095, Fig. 9B). For the non-motor activity, the same phenomenon was 
observed with no significant change during the dark phase (6.7709 ± 0.2537 Hz v. 
6.2876 ± 0.2294 Hz, Fig. 9F), a significant trend for the total observation period 
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(6.9171 ± 0.2161 Hz v. 6.3187 ± 0.2092 Hz, p = 0.082, Fig. 9D) and a significant 
reduction during the light phase (7.0632 ± 0.2170 Hz v. 6.3498 ± 0.2077 Hz, p = 0.045, 
Fig. 9E). No significant differences were observed for motor activities (light and dark: 
7.1707 ± 0.3754 Hz v. 6.6851 ± 0.1848 Hz; light: 7.1214 ± 0.3250 Hz v. 6.6066 ± 
0.1752 Hz; dark: 7.2327 ± 0.4162 Hz v. 6.7580 ± 0.2253 Hz). Finally, the mean theta 
amplitudes were calculated. For the total recording period, no changes in theta 
amplitude could be detected (light and dark: 0.0192 ± 0.0039 mV v. 0.0183 ± 0.0031 
mV, light: 0.0194 ± 0.0040 mV v. 0.0184 ± 0.0033 mV; dark: 0.0189 ± 0.0039 mV v. 
0.0183 ± 0.0029 mV). The same hold true for the non-motor activity (light and dark: 
0.0199 ± 0.0039 mV v. 0.0183 ± 0.0030 mV; light: 0.0204 ± 0.0040 mV v. 0.0184 ± 
0.0032 mV, dark: 0.0193 ± 0.0038 mV v. 0.0181 ± 0.0028 mV) and non-motoric phase. 
This finding correlates with previous observations in 5XFAD but also TgCRND8 mice 
(Goutagny and Krantic, 2013). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9: Theta-frequency in controls and 5XFAD mice. The mean theta frequency 
was calculated for the total observation period (48 h, A-C), no motor activity (D-F) and 
motor activity (not shown). In all cases, theta frequency is reduced. Again, this 
reduction turned out to be significant during no motor activity (E).  
 
Urethane induced hippocampal theta oscillations in controls and 5XFAD mice 
Besides analysis of spontaneous theta activity, we also investigated urethane induced 
theta oscillations. Pharmacodynamically, urethane has a multi-target character capable 
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of inducing atropine-sensitive type II theta. Theta oscillations were analyzed for 30 min 
baseline and 30 min post injection episodes (Fig. 10). The duration of hippocampal 
theta oscillations for the total analytical period, i.e. including theta oscillations during 
episodes with either motor or non-motor activity, was increased in control mice (1.59 ± 
0.47 min/h to 4.20 ± 1.40 min/h, n = 4) as in 5XFAD mice (5.09 ± 2.06 min/h to 18.08 
± 6.25 min/h, n = 4) and where the factor “experimental condition/urethane effect” 
shows a significance (p = 0.036). The factor “genotype” exhibited a statistical trend (p = 
0.062) (Fig. 10A).  
 
 
 
 
 
 
 
 
 
 
Figure 10: Urethane induced hippocampal theta oscillations in control and 5XFAD 
mice. CA1 hippocampal theta recordings from both genotypes were analyzed for 
duration of atropine-sensitive type II theta oscillations regarding total observation 
period (A) and non-motor episodes (B). In addition, theta frequency was calculated for 
total duration (C) and non-motor episodes (D).  
 
As type II theta is characteristic of alert immobility data were also analyzed for non-
motor activity EEG segments. As expected, the results matched those for the total 
analytical period, i.e. a significant effect for the factor “experimental condition/urethane 
effect” (p = 0.032) with increase in controls (1.45 ± 0.48 min/h to 3.88 ± 1.52 min/h, n 
= 4) and 5XFAD mice (4.11 ± 1.59 min/h to 15.78 ± 5.34 min/h, n = 4). The factor 
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“genotype” exhibited a statistical trend (p = 0.064) (Fig. 10B). These findings 
demonstrate that 5XFAD mice even of higher age are capable of displaying increased 
theta oscillations upon urethane provocation. However, it remains to be determined 
whether such theta activity is physiologically integrated or the result of hyperactive, 
functionally dislinked neuronal clusters within the hippocampus. Interestingly, besides 
an effect for theta-duration, there was a significant effect for the factor “experimental 
condition/urethane effect” (p = 0.010) on theta oscillation frequency for the total 
analytical period (6.57 ± 0.61 Hz to 5.48 ± 0.36 Hz, (n = 4) in controls versus 6.18 ± 
0.31 Hz to 5.11 ± 0.33 Hz (n = 4) in 5XFAD mice) (Fig. 10C). This significant effect (p 
= 0.030) also hold true for the non-motor episodes (6.60 ± 0.63 Hz to 5.44 ± 0.35 Hz (n 
= 4) in controls versus 6.14 ± 0.53 Hz to 5.15 ± 0.36 (n = 4) in 5XFAD mice (Fig. 
10D).  
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Discussion 
Alzheimer’s disease is a complex neurodegenerative disorder accompanied by cognitive 
impairment that ultimately leads to dementia. In the present study, we investigated 
transcriptional alterations and the EEG phenotype of 5XFAD mice. This mouse model 
harbors five early-onset familial FAD mutations and displays substantial Aß plaques 
and neurodegeneration (Crouzin et al., 2013; Eimer and Vassar, 2013). Our study 
demonstrates that 5XFAD mice exhibit non-convulsive seizure activity of different 
severity, predominantly in the M1 deflection, whereas there was hardly any seizure 
activity in the CA1 recordings. It’s noteworthy that Aß formation in certain mouse 
models can differentially alter cholinergically induced rhythmicity according to the 
structure of Aβ plaques (Crouzin et al., 2013) and therefore leading to different 
phenotypes of seizure activity. In addition, stereological quantification of pyramidal 
neurons of the CA1 layer showed no significant difference between the number of 
neurons of WT and 5XFAD mice, however a significant loss was detected in cortical 
layer 5 (Crouzin et al., 2013). A single 5XFAD mouse exhibited status like generalized 
tonic-clonic seizures and early death and thus was not included into the study analysis. 
Experimental studies in genetically engineered mice support these findings, highlighting 
the presence of subclinical seizures and overlapping pathophysiological cascades 
(Noebels, 2011). Lowered convulsant thresholds and spontaneous convulsive seizure 
phenotypes have been observed in AD mouse models (Kumar et al., 2000; LaFerla et 
al., 1995; Lalonde et al., 2005; Moechars et al., 1996). Interestingly, deletion of APP 
(Steinbach et al., 1998) and BACE1, the secretase that participates in Aß release (Hu et 
al., 2010) also causes an epileptic phenotype, indicating that normal APP signaling is 
important for the development of hippocampal excitability (Minkeviciene et al., 2009). 
In some models, lower thresholds for induced or spontaneous seizures are found even in 
the absence of amyloid deposits, further stressing the role of soluble forms of Aß as a 
pathogen (Kumar et al., 2000; Steinbach et al., 1998). Chronic EEG monitoring in J20 
mice overexpressing hAPP (Palop et al., 2007) revealed that most frequent seizures 
were purely electroencephalographic, i.e. non-convulsive without complete motoric 
arrest as observed in our study using 5XFAD mice (Palop et al., 2007; Palop and 
Mucke, 2009). Similarly, in rare cases motor seizures were observed. This observation 
raises the question whether abnormal hippocampal neuronal synchronization remains 
undetected in human AD patients, and whether this network level abnormality might 
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accelerate a more rapid cognitive decline in patients suffering from FAD (Palop et al., 
2006; Palop et al., 2007; Pandis and Scarmeas, 2012). Histological evaluation of the J20 
mouse hippocampus revealed striking evidence for hippocampal network remodeling 
that is similar, but not identical, to the changes identified in both patients with temporal 
lobe epilepsy and experimental models of hippocampal seizures. The cellular changes 
included ectopic sprouting of dentate granule cell mossy fibres and sprouting of fibers 
containing the inhibitory neurotransmitter NPY (de Lanerolle et al., 1989; Sutula et al., 
1989). Convulsive seizures with associated hippocampal network plasticity have been 
confirmed in other AD mouse models (Minkeviciene et al., 2008; Minkeviciene et al., 
2009; Sutula et al., 1989). Interestingly, impairments of GABA transmission in the J20 
brain provide an interesting basis for epileptogenesis in these models. Increased adult 
neurogenesis is found in both human AD and temporal lobe epilepsy (TLE) cases (Jin et 
al., 2004; Sutula et al., 1989). The multiple lines of evidence discussed above show that 
soluble forms of Aß are cytotoxic inducing the appearance of aberrant excitatory 
neuronal network activity in vivo, and triggering complex molecular and cellular 
patterns of compensatory inhibitory and excitatory mechanisms in hippocampal 
circuitry (Amatniek et al., 2006; Goutagny and Krantic, 2013; Hauser et al., 1986; 
Pandis and Scarmeas, 2012; Westmark et al., 2008). The toxic accumulation of Aß 
peptides underlying Alzheimer's disease (AD) triggers synaptic degeneration, circuit 
remodeling, and abnormal synchronization within the same networks. Because neuronal 
hyperexcitability amplifies the synaptic release of Aß, seizures create a vicious spiral 
that accelerates cell death and cognitive decline in the AD brain (Chin and Scharfman, 
2013). While degenerative processes in the nervous system ultimately result in loss of 
neural signaling, when active inhibitory mechanisms fail early, the resulting 
disinhibition may destabilize network oscillatory activity at formative stages of the 
disease. 
How can seizure activity correlate with altered theta oscillations in the hippocampus? 
Complex cognitive operations are depended on a sophisticated coordination of activity 
across a plethora of neuronal groups. One of the most intriguing mechanisms for 
neuronal coordination and communication is through neuronal synchronization by brain 
oscillations (Womelsdorf et al., 2007). Theta oscillations represent one of these 
oscillations and are modulated by specific behavioural and cognitive states and are 
related to memory deficits, e.g. in AD (Buzsaki, 2002; Chin and Scharfman, 2013; 
Gutierrez-Lerma et al., 2013; Moretti et al., 2010; Palop et al., 2007; Pena-Ortega and 
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Bernal-Pedraza, 2012). Disruption of theta activity results in spatial memory deficits, 
whereas the restoration of theta-like rhythmicity restores learning capabilities in rats 
(McNaughton et al., 2006). Theta duration analysis in our study suggests an increase of 
theta oscillations in 5XFAD mice during the dark phase. This phenomenon was most 
prominent during the switch from light to dark phase and non-motor activity. As 
analysis of motor/non-motor activity did not reveal any difference between controls and 
5XFAD mice, the difference in theta duration is likely to be based on theta-subtype 
composition. We speculate that mice in the non-active dark phase predominately exhibit 
alert-immobility which is characterized by atropine-sensitive type II theta (Bland et al., 
1996; Shin et al., 2005). As in our study, a statistical trend for an increase in theta 
duration has been described in the TgCRND8 mouse model (Goutagny and Krantic, 
2013). These changes in theta duration in 5XFAD mice are an important variable 
because they are known to be associated with memory effectiveness. Animals 
displaying a higher amount of theta activity are faster in novel task learning than 
animals that exhibit less pronounced theta oscillations (Berry et al., 1978; Moretti et al., 
2010). Unlike the common assumption of decreased theta activity in dementia, an 
increase in theta activity is observed in various mouse models of AD. Administration of 
urethane to induce hippocampal type II theta clearly proved that 5XFAD mice can 
exhibit increased atropine sensitive theta oscillations upon provocation (Fig. 7A,B). 
One might speculate that hyperexcitable neuronal clusters surrounded by degenerated 
neurons might account for this increase in theta which disrupts the ability of neuronal 
networks to dynamically adjust the amplitude of these oscillations during memory 
processes. Interestingly, the mean theta frequency was reduced in 5XFAD mice, i.e. 
theta oscillations turned out to be significantly slower than in control animals. This 
phenomenon is commonly observed in Alzheimer patients (Czigler et al., 2008; Jelic et 
al., 2000; Jelic and Nordberg, 2000; Moretti et al., 2010). It has been suggested that 
theta frequency could change as a function of novelty and familiarity (Jeewajee et al., 
2008). Thus, the significant decrease in theta frequency could dramatically skew the 
delicate balance of theta frequency dynamics between novelty and familiarity. Previous 
studies have shown that the muscarinic signaling transduction cascade (Felder, 1995) is 
severely affected in AD, e.g. carbachol-induced PKC activation is disrupted by Aß 
(Huang et al., 2009) that might correlate with a very slight down-regulation of PLC1 as 
observed in our study (Fig. 11). Cav2.3 voltage-gated Ca
2+
 channels are involved in both 
the generation of cellular correlates of ictal discharges, i.e. afterdepolarisation and 
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plateau potentials (Kuzmiski et al., 2005; Tai et al., 2006) and the generation of 
atropine-sensitive type II theta (Jansen et al., 2011; Muller et al., 2012; Shin et al., 2005; 
Shin et al., 2009). Transcriptome analysis of 5XFAD hippocampal probes performed in 
this study suggests an upregulation of PLCd4 which could results in type II theta 
acceleration via the PKC, Cav2.3 cascade (Muller et al., 2012) however, other 
muscarinic signaling targets could also be involved (Fig. 11).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11: Functional integration of seizure activity and theta oscillations in the 
5XFAD model of Alzheimer’s disease. Time-frequency analysis in 5XFAD mice 
revealed changes in theta duration and theta frequency which are related to no motor 
activity, particularly during the dark phase. Under these conditions, the animals either 
sleep or rest. Hippocampal activity during the state of alert immobility is characterized 
by atropine-sensitive type II theta, which is related to the muscarinic signal transduction 
pathway. Activation of PLC was shown to enhance Ca
2+
 influx via Cav2.3 R-type Ca
2+
 
channels which can lead to the generation of epileptiform burst activity via CNG 
mediated plateau potentials. However, Cav2.3 R-type channels were also shown to be 
involved in the generation of hippocampal theta oscillations. Enhanced transcription of 
PLCd4 might thus trigger both enhanced theta duration and theta frequency alteration in 
5XFAD mice but also seizure activity in this severe model of AD. 
 
Summing up, we conclude that Aβ accumulation in 5XFAD mice results in altered 
muscarinic signaling that accounts for both seizure activity and altered theta 
architecture. Although some caution is warranted in interpreting results from the 
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aggressive amyloid mouse model 5XFAD that over expresses multiple FAD mutations 
as, our results stress that pharmacological interference with muscarinic signaling is a 
valuable target in AD treatment. Finally, our study suggests that alterations in theta 
characteristics might serve as a diagnostic and prognostic biomarker in AD in the 
future. 
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Supplement 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 1: Characteristics of theta amplitude in control and 5XFAD 
mice. The theta-alpha band was analysed using a time-frequency approach. Behavioural 
artefacts were removed using an algorithm as described above. Amplitude was 
calculated for both genotypes for the total observation period (A) and the light (B) and 
dark (C) phase, respectively. Total and phase-specific analysis was also done for non-
motor activity (D-F) and motor activity (not shown). No difference was observed 
between both genotypes. 
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Supplementary Table 1: Representation of interesting candidate genes revealed 
from microarray analysis. The absolute fold change (AFC) between transgenic 
Alzheimer’s 5XFAD mice and WT control littermates. 
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Supplementary Table 2: Presentation of candidate genes revealed from microarray 
analysis with absolute fold change (AFC) > 2 between transgenic Alzheimer’s 
5XFAD (TG) mice and WT control littermates (WT). Gene ontology analysis 
revealed that the strongest transcriptional alterations belong to immune-response and 
inflammation related genes observed in the context of late-stage cerebral amyloidosis. 
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3. Discussion 
Previous studies address the crucial role of VGCCs in etiology and pathogenesis of theta 
rhythms and seizure activity. Herby, the Cav2.3 R-type Ca
2+ 
channel is likely to be 
important in hippocampal (Metz et al., 2005) and thalamocortical circuits (Zaman et al., 
2011) providing its overall extraordinary function in certain central rhythmicity. Based 
on these recent findings, it is a question of debate how electrophysiological alterations 
in theta activity can share at least in some aspects similar underlying mechanisms that 
are potentially existing for sleep disorders, AD and seizure susceptibility.  
Here, we demonstrate that sleep architecture is fundamentally modulated by Cav2.3 R-
type Ca
2+
 channels in a light-dark dependent manner. Cav2.3
-/- 
mice show significantly 
decreased wake duration and increased SWS1 compared to their WT littermates 
indicating an abbreviation of sleep stage transitions. Therefore, we conclude that the 
functional role of Cav2.3 R-type Ca
2+
 channels in sleep regulation might be related to 
the synchronization of oscillatory activity in the TC network. Changes in sleep stage 
transitions shown in our study are furthermore supported by sleep scoring results from 
pharmacologically induced SWS after urethane administration. Following urethane 
injection Cav2.3
-/- 
mice exhibit increased SWS1 and decreased wake duration in 
comparison to Cav2.3
+/+ 
animals. However, it has to be pointed out that urethane is a 
multi-targeting drug not exclusively effecting one specific signaling pathway. Urethane 
at a dosage of 800mg/kg i.p used in our study elites light SWS but not deep anasthesia. 
Previous studies demonstrated that TC rhythmicity can be differentially modulated 
according the pharmacodynamic profiles of several anesthetics (Takei et al., 2003). For 
instance, isoflurane is capable of inhibiting presynaptic Cav2.3 R-type Ca
2+ 
channels 
which are necessary for inhibitory GABAA transmission in RTN cells but leads to an 
inhibition of T-type currents as well (Joksovic et al., 2005; Joksovic et al., 2009; 
Todorovic et al., 2000). Thus, it still remains striking to predict the final consequences 
of anesthetics on the TC system. Analysis of sleep deprivation in Cav2.3
-/- 
mice revealed 
a non-significant trend of higher delta amplitude in Cav2.3
-/- 
mice in comparison to WTs 
suggesting a less impact of sleep deprivation provoked by TC hyperoscillations. In line 
with this, Zaman et al. recently illustrated that Cav2.3 R-type Ca
2+
 channels promote 
rebound burst firing in RTN neurons through the activation of SK2 channels. Taken this 
finding into consideration, it seems astonishing that ablation of Cav2.3 R-type Ca
2+ 
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channels did not result in decreased SWS as illustrated in our study. To explain this 
initially controversial observation one has to keep in mind that initiation and regulation 
of sleep is not uniquely restricted to the RTN physiology but also includes the 
functional involvement of LVA Cav3.1-3.3 T-type Ca
2+ 
channels, HCN and non-specific 
cation channels as well as extrathalamocortical sleep modulators. Within the TC system 
relay cells and RTN neurons represent a functional unit. For instance, region specific 
deletion of 3.1 T-type Ca
2+ 
channels results in lack of Cav3.1 triggered Ca
2+ 
influx in 
relay cells finally leading to altered burst activity that is in line with massive sleep 
disruption as recently demonstrated  by Lee et al., 2004. Unlike the deletion of Cav3.1 
T-type Ca
2+ 
channels, blockade of Cav3.2 T-type Ca
2+ 
channels is related to enhanced 
sleep duration, whereas sleep architecture remains to be altered (Lee and Shin, 2007). 
These findings clearly illustrate the complex nature of TC rhythmicity and the 
contribution of VGCC as its functional modulators. To test possible compensatory 
mechanisms on TC rhythmicity by T-type Ca
2+ 
channels, we preformed qPCR 
experiments. Our results depict no significant changes in T-tpye Ca
2+ 
channel 
expression indicating that no thalamic disruption in these Ca
2+ 
channels can account for 
changed oscillatory pattern in Cav2.3
-/- 
mice. However, we are not able to assume this 
for the extrathalamocortical regions as well. Extrathalamocortical structures like the 
hippocampus, the basalganglia, mesopontine REM-NREM neuronal entities in the ACE 
and hypothalamic nuclei can act as sleep onset controllers and modulators. Therefore, 
they are able to influence oscillatory activity in the TC system substantially (Deransart 
et al., 1998; Khosravani and Zamponi, 2006; Manning et al., 2003; Pace-Schott and 
Hobson, 2002) by regulating excitability in Wake-ON, REM-ON and NREM-ON cell 
entities of the ACE via Cav2.3 R-type based Ca
2+ 
current (Lee et al., 2002). Our results 
might be indeed considerable for the isolated TC system in vivo. However, they are not 
sufficient enough to explain all molecular mechanisms in detail. For elucidating the 
functional role of Cav2.3 R-type Ca
2+ 
channels in the TC system  more precisely and 
drawing our understanding on  TC rhythmicity one step closer, future studies on sleep 
architecture have to consider investigations of extrathalamocortical structures as well. In 
terms of a global neuronal network it is furthermore necessary to look at altered 
properties of VGCC and neuronal ensembles under pathophysiological conditions like 
occurring in AD. AD is an age-related neurodegenerative disorder characterized by 
impairment of memory function and massive synaptic loss. Because highly 
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synchronized neuronal activity is mandatory for proper cognitive functions, imbalance 
of inhibitory and excitatory processes can finally contribute to disruption in oscillatory 
rhythmicity (Kordower et al., 2001; Morrison and Hof, 1997; Price et al., 2001; Terry et 
al., 1991). In this regard, recent investigations suggest that accumulation of soluble Aß 
in AD is capable of eliciting reorganisation in neuronal networks resulting in seizure 
activity. Previously, it was believed that seizure activity marks a secondary process 
which is closely related to age-dependent neurodegeneration within the hippocampus 
and the entorhinal cortex (Deipolyi et al., 2007; Deipolyi et al., 2008). Nowadays this 
notion might be seen more in context of animal models indicating that altered excitatory 
neuronal activity represents rather a primary upstream mechanism than being related to 
secondary processes of neurodegeneration. Observations in patients with AD also stress 
this assumption. It could be shown that increased incidence of unprovoked seizures 
appears independently of disease stages in sporadic form of AD (Amatniek et al., 2006). 
However, it has to be pointed out that a whole causal interdependence between high 
levels of Aß peptide and cognitive decline in humans still remains to be not fully 
understood. Animal models of AD so far provide important and indispensable tools for 
investigations on pathophysiological neuronal interactions but they are always limited to 
the experimental issue they are referring to. In accordance to the complex nature of AD, 
it is still striking to determine whether given changes in signaling cascades drive disease 
pathology or simply illustrate diffused responses of neuronal activity or increased 
seizure susceptibility. To set light on this issue, we investigated the electrophysiological 
and behavioural phenotype of the 5XFAD mouse model of familial AD to dissect the 
causal relationship between Aß-induced aberrant neuronal activity and cognitive decline 
and furthermore to provide evidence for possible protective effects on seizure 
susceptibility. Pathophysiological cell signaling is strongly related to the presence of 
subclinical seizure activity (Noebels, 2011). Deletion of APP causes epileptic 
phenotypes indicating the importance of APP signaling in proper hippocampal 
excitability (Steinbach et al., 1998). In addition, recent studies suggested that elevated 
phosphorylated levels of elF2α lead to increased expression of ATF4 and BACE1 
promoting inhibition of synaptic plasticity and enhanced accumulation of Aß plaques in 
the brain (Hu et al., 2010). Aß peptides trigger synaptic loss and neuronal degeneration, 
finally complementing the vicious circle of neuronal remodeling, hyperexcitability and 
cell death. In conjunction with previous findings, genetic deletion of elF2α results in 
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restored neuronal plasticity in APP/PS1 mice (Ma et al., 2013). Hence, we hypothesize a 
possible rescue effect of non-phosphorylatable elF2α allele (elF2αS51A) on learning and 
memory impairments and epileptiform seizure activity in 5XFAD mice. Our study 
demonstrates that seizure activity in 5XFAD mice is characterized by 
electroencephalographic ictal graphoelements predominantly in the motor cortex (M1). 
5XFAD mice exhibit a subclinical or non-convulsive phenotype depicting episodes or 
spike trains, poly-spike and spike-wave activity in the M1 recording which was hardly 
found in the hippocampal CA1 deflection. In agreement, recent data revealed that in 
mouse models overexpressing hAPP (Palop et al., 2007) most seizures remained to be 
non-conclusive without any motoric exacerbation. Seizure detection scoring including 
number and duration of episodes and spikes showed that seizure activity did not 
significantly differ between the individual transgenic mouse genotypes. Hence, 5XFAD 
mice expressing the non-phosphorylatable elF2α variant are not retarded concerning 
amyloidgenesis progression. Enhanced motor activity levels as well as seizure activity 
can be a result of differentially affected cholinergic neuronal loss according to structure 
and length of Aß peptides (Crouzin et al., 2013; Gutierrez-Lerma et al., 2013). 
Concerning this,  Aß formation leads to a more profoundly impaired LTP in the 
somatosensory cortex of 5XFAD mice, especially in the cortical layer 5, compared to 
the hippocampal CA1 region as illustrated in previous studies (Crouzin et al., 2013). 
Although hippocampal ChAT expression was reduced in our study, we could not depict 
any differences between 5XFAD WTs and 5XFAD;elF2α+/S51A mice. Consequently, we 
could show that the non-phoshorylated elF2α allele has no preventive effect on the 
aberrant cholinergic system from exhibiting seizure-like activity in 5XFAD mice. This 
might be due to the fact that heterozygous elF2α mutants are less effective in 
suppressing kinase phosphorylation in comparison to homozygous deletion of elF2α that 
results in reduced p-elF2α level in the APP/PSEN1 mouse model (Ma et al., 2013). The 
limited effects on behavioural performance in our study furthermore support our 
assumption. 5XFAD mice show higher active suppression scores in fear conditioning 
paradigm and less use of hippocampal dependent strategies indicating cognitive 
impairment. However, all effects were not significantly improved by the heterozygous 
elF2α mutation. To verify a possible correlation between hippocampal theta oscillations 
and seizure activity, we performed time-frequency analysis on theta duration. Theta 
activity is related to memory impairment in AD (Buzsaki, 2002; Chin and Scharfman, 
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2013; Gutierrez-Lerma et al., 2013; Palop et al., 2007) and can be modified by different 
behavioural states (Buzsaki, 2002). Restoration of theta rhythmicity is capable of 
improving learning and memory functions as well as inhibiting seizure production 
which correlates with neuronal desynchronization (Colom, 2006). Our results display a 
significant increase in theta activity from the light to dark phase during non-motor 
activity in 5XFAD mice. Due to the theta-subtype composition, we consider 5XFAD 
mice to mainly exhibit alert-immobility during the non-active dark phase. Alert 
immobility is characterized by atropine-sensitive type II theta (Bland et al., 1996; Shin 
et al., 2005)  indicating the muscarinic pathway to be crucial involved in immobility 
onset. Unlike the assumption that cognitive decline would be necessarily related to a 
decrease of theta activity, an increase of theta power can be also found in the TgCRND8 
mouse model (Goutagny et al., 2013). Because theta activity is required for successful 
recall and memory formation (Rutishauser et al., 2010), it is fair to expect that higher 
amount of theta activity result from hyperexcitability of healthy neurons contributing to 
the adjustment of dynamical changes and cellular disruption in neuronal networks. 
Furthermore, we observed a reduction in mean theta frequency in 5XFAD mice 
compared to controls. This effect was again predominantly detected during non-motor 
activity. Opposing trends in theta amplitude and frequency can be understood as 
phenomena occurring in a complex but unbalanced neuronal system (Pena-Ortega and 
Bernal-Pedraza, 2012). Slower theta oscillations being observed in patients with AD 
(Jelic et al., 2000; Jelic and Nordberg, 2000) are supposed to represent changes in 
hippocampal novelty and familiarity detection (Jeewajee et al., 2008). However, it has 
to be put under consideration if changes in theta rhythms might serve as a possible 
predictor for disease progression. Despite the evidence obtained from cell biology and 
genetics, recent studies confirmed that the amyloid hypothesis alone cannot account for 
the entire AD pathology. Changes in theta activity can even arise before Aß 
accumulation (Goutagny et al., 2013; Goutagny and Krantic, 2013) indicating that 
network over-excitation is not sufficiently linked to overproduction of Aß plaque 
deposits. Neuroimaging studies in humans showed that amyloid deposits can be missing 
in patient with AD, whereas being present in cognitively healthy individuals (Edison 
2007, Li Y 2008).These findings raise the question, how mutations in PSEN1 and APP 
contribute to profound AD pathology independently from elevated Aß levels. Hence, 
future studies on AD should address to this topic by distinguishing between different 
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APP forms and taking non-amyloid factors into consideration (Pimplikar et al., 2010; 
Pimplikar, 2012). Transcriptome analyses performed from hippocampal RNA tissue 
revealed an upregulation of PLCδ4 shedding light on a potentially enhanced muscarinic 
signalling resulting in enhanced type II theta acceleration via the Cav2.3 mediated PKC 
cascade (Muller et al., 2012). Alterations in the muscarinic signal transduction in 
5XFAD and other mouse models of AD (Felder, 1995) are involved in theta genesis as 
well as ictogenesis suggesting to be accountable for hippocampal dysrhythmicity (Tai et 
al., 2006). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 117 
 
4. Conclusion 
Summing up, our results provide new insights into how oscillatory activity is attended 
by physiological and pathophysiological conditions and how oscillations within a 
neuronal network can be shaped on a molecular level. In this regard, we demonstrated 
that sleep architecture is substantially modified by the Cav2.3 R-type Ca
2+ 
channel. 
Although detailed mechanisms and modulatory effects of especially 
extrathalamocortical structures on the TC system have still to be determined, the Cav2.3 
R-type Ca
2+ 
channel provides a potential target for treatment of sleep disorders. In 
special regard to AD, our findings account for a better understanding of the disease 
pathology by demonstrating the functional and pharmacological interference between 
Aß plaques, the muscarinic cascade and theta activity. However, it has to be critically 
questioned, how disease related mechanisms found in FAD can be transferred to the 
sporadic, more common form of AD. In the future, it will be necessary to require 
specific genetically engineered mouse models to assess the molecular and behavioural 
consequences of AD and to evaluate the muscarinic signaling pathway as potential 
target cascade in AD treatment. 
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